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Dopaminergic (DA) neuron development is a complex process, combining and 
coordinating the precise expression of numerous molecules. The importance of understanding 
this process is based on the growing interest in being able to reproduce their proper 
differentiation in vitro, in order to provide new treatment options for Parkinson’s Disease (PD). 
However, obtaining DA neurons that are biologically, chemically and physiologically 
equivalent to those found in the brain is a complicated process, and for that reason it is important 
to investigate how these neurons develop in their normal physiological context.  
 
We are investigating the role of the protein p27Kip1 (p27) in the differentiation process 
of these neurons. p27 is a cyclin/cyclin dependent kinase inhibitor (CKI) belonging to 
the Cip/Kip family of proteins. p27 is best known for its function in the cell cycle, where it 
specifically inhibits cyclin and cyclin dependent kinases (CDKs) of the G1 phase, and it is 
mainly regulated through controlling its degradation. However, in recent years, p27 has also 
been shown to have important implications outside of the cell cycle, including promoting 
primary neurogenesis in the cortex, inhibiting the transcription factor Sox2 and in promoting 
the differentiation of DA neurospheres. 
 
In the context of the ventral mesencephalon (VM), we see that p27 deficiency appears 
to have a specific effect on DA neuron production, significantly decreasing the early 
differentiation of these neurons in vivo and in vitro. Interestingly, these differences are 
accompanied by an increased pool of neural precursors, increasing Sox2 and Ngn2 expression. 
However, despite these increases, downstream targets of Ngn2 (such as NeuroD1) necessary to 
promote progenitor progression towards mature DA neuronal phenotypes are diminished. We 
therefore suggest a novel role of p27 in regulating proper cell cycle exit to promote appropriate 
activation of genes involved in neurogenesis. This knowledge would allow us to better apply 
the use of this protein to improve current differentiation protocols of DA neurons for stem cell 








El desarrollo de las neuronas dopaminérgicas (ND) es un proceso muy complejo, que 
combina la expresión de varias moléculas en un contexto muy específico. La importancia de 
entender este proceso se basa en el interés de reproducir el proceso de diferenciación in vitro, 
con el fin de buscar posibles terapias para la enfermedad de Parkinson (EP). Sin embargo, la 
obtención de ND in vitro, equivalentes a las del cerebro en relación a su biología, química y 
fisiología, es un proceso muy complicado y, por lo tanto, la investigación de cómo esas 
neuronas se desarrollan en su entorno normal es muy importante.  
 
Estamos investigando la función de la proteína p27Kip1 (p27) en la diferenciación de 
ND. p27 es un inhibidor de ciclinas/ciclinas dependiente de kinasas (CDKs) que pertenece a la 
familia de proteínas Cip/Kip. La función más conocida de p27 es el papel que juega en el ciclo 
celular, donde inhibe ciclinas y CDKs de la fase G1, y su regulación está mayormente 
controlada a través de su degradación. No obstante, se ha visto que p27 tiene funciones 
importantes fuera de su papel en el ciclo celular, como promover neurogénesis en la corteza 
cerebral, inhibir el factor de transcripción Sox2 (marcador de precursores neurales) y promover 
la diferenciación de neuroesferas de ND.  
 
En el contexto del mesencéfalo ventral (MV), hemos visto que la deficiencia de p27 
tiene un efecto específico en la producción de las ND, disminuyendo de manera significativa la 
diferenciación de estas neuronas tanto in vivo como in vitro. Estas diferencias van acompañadas 
con un aumento en el numero de precursores neurales, aumentando la expresión de factores 
como Sox2 y Ngn2. Sin embargo, a pesar de ver un incremento en el número de precursores, 
dianas “downstream” de Ngn2, como sería el marcador NeuroD1 (que es necesario para 
promover la progresión de progenitores hacía ND maduras), está disminuido. Por lo tanto, 
nuestro trabajo sugiere un papel nuevo de p27 en la regulación del ciclo celular para promover 
y activar los genes necesarios para neurogénesis. Estos resultados podrían ser importantes para 
ayudar a mejorar los protocolos actuales de diferenciación de ND, y para futuras terapias de 
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• α-MEM: Minimum essential medium with α-modification 
• α-syn:  α-synuclein 
• AA: Ascorbic acid 
• Ascl1 or Mash1: Achaete scute homolog 
• BDNF: Brain derived neurotrophic factor 
• bHLH: Basic helix loop helix 
• BSA: Bovine serum albumin 
• CDK: Cyclin dependent kinase 
• CKI: Cyclin/cyclin dependent kinase inhibitor 
• CNS: Central nervous system 
• DA: Dopaminergic neurons 
• DAT: Dopamine transporter 
• DBS: Deep brain stimulation 
• DM: Dorsal mesencephalon 
• DMEM: Dulbecco’s modified eagle medium 
• DNA: Deoxyribonucleic acid 
• dNTP: Deoxyribonucleotide triphosphate  
• DRD2: Dopamine d2 receptor 
• DTT: Dithiothreitol 
• EB: Embryoid body 
• EDTA: Ethylenediaminetetraacetic acid 
• EP: Enfermedad de Parkinson 
• ESC: Embryonic stem cell 
• FBS: Fetal bovine serum 
• Ferd31: Fer3 like bHLH transcription factor 
• FGF2: Fibroblast growth factor 2 
• FGF8: Fibroblast growth factor 8 
• Foxa2: Forkhead box A2 
• FP: Floor plate 
• G1: Growth phase 1 
• G2: Growth phase 2 
18 
• Gbx2: Gastrulation homeobox 2 
• GDNF: Glial-cell derived neurotrophic factor 
• HBSS: Hank’s buffered saline solution 
• Hes1: Hairy and enhancer of split-1 
• Hes5: Hairy and enhancer of split-5 
• ICC: Immunocytochemistry 
• IHC: Immunohistochemistry 
• iPSC: Induced pluripotent stem cell 
• IsO: Isthmic organizer 
• IZ: Intermediate zone 
• KID: Kinase inhibitory domain 
• KO-DMEM: Knock-out Dulbecco’s modified eagle medium 
• L-dopa: Levodopa 
• LB: Lysogeny broth  
• LD: Linker domain 
• Lif: Leukemia inhibitory factor 
• Lmx1a: LIM homeobox transcription factor 1, alpha 
• Lmx1b: LIM homeobox transcription factor 1, beta 
• M: Mitosis 
• MEF: Mouse embryonic fibroblast 
• MeSC: Mesenchymal stem cell 
• MHB: Midbrain/hindbrain boundary 
• miPSC: Mouse induced pluripotent stem cell 
• MSC: Multipotent stem cell 
• Msx1: Msh homeobox 1 
• MV: Mesencéfalo ventral 
• MZ: Mantle zone 
• ND: Neuronas dopaminérgicas 
• NEAA: Non-essential amino acids 
• NES: Nuclear export signal 
• Ngn2: Neurogenin 2 
• NHS: Normal horse serum 
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• NLS: Nuclear localization signal 
• NSC: Neural stem cell 
• Nurr1: Nuclear receptor related protein-1 
• Otx2: Orthodenticle homeobox 2 
• P/S: Penicillin/streptomycin 
• p21: p21Cip1 
• p27: p27Kip1 
• p57: p57Kip2 
• PBS: Phosphate-buffered saline 
• PCR: Polymerase chain reaction 
• PD: Parkinson’s Disease 
• PFA: Paraformaldehyde 
• Pitx3: Pituitary homeobox 3 
• PNS: Peripheral nervous system 
• PSC: Pluripotent stem cell 
• Rb: Retinoblastoma 
• RNA: Ribonucleic acid 
• RrF: Retrorubral area 
• RT-qPCR: Real time-quantitative polymerase chain reaction 
• S: Synthesis phase 
• SB: Sodium butyrate 
• SCF Complex: Skp, Cullin, F box containing complex 
• Shh: Sonic hedgehog 
• Skp1: S-phase kinase associated protein 1 
• Skp2: S-phase kinase associated protein 2 
• SN: Substantia nigra 
• Sox2: SRY-box 2 
• SR: Serum replacement 
• Subdomain D1: Cyclin binding subdomain D1 
• Subdomain D2: Cyclin binding subdomain D2 
• TBS: Tris buffered saline 
• TGF-ß: Transforming growth factor beta 
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• TH: Tyrosine hydroxylase 
• USC: Unipotent stem cell 
• VM or midbrain: Ventral mesencephalon 
• Vmat2: Vesicular monoamine transporter 2 
• VTA: Ventral tegmental area 
• VZ: Ventricular zone 
• WB: Western blot 












































































1. PARKINSON’S DISEASE 
Parkinson’s Disease (PD) is a chronic neurodegenerative disorder, first described by 
James Parkinson in his article An Essay on the Shaking Palsy (Parkinson 1817). This marked 
the beginning of what became, and remains to this day, an intense area of research, as we race 
against time trying to understand the molecular and pathophysiological mechanism leading to 
the development of PD and to discover new and effective treatment options that can repair these 
pathological processes.  
PD is the second most common neurodegenerative disorder, affecting 1-2% of the 
population over the age of 65 (Poewe et al 2017). Age is the main risk factor, where the 
prevalence and incidence increase almost exponentially with age, and peaks after the age of 80 
(Poewe et al 2017). There are an estimated 6.1 million cases worldwide, with about 700,000 
cases in the United States, 830,000 cases in Western Europe and almost 100,000 cases in Spain 
(García Ramos et al 2016, GBD 2016 Parkinson’s Disease Collaborators, 2018). With an aging 
population, the impact of this disease becomes a major public health issue, and the incidence is 
expected to double by 2050 (Rocca 2018). Therefore, there is an urgent need for research 
focused on finding new preventative treatments to halt, alter or reverse the progression of PD.  
1.1 Pathology and Etiology 
Today, PD is commonly characterized by the loss of A9 nigrostriatal dopaminergic 
(DA) neurons in the midbrain (González et al 2015, Poewe et al 2017) and the presence of α-
synuclein (α-syn) rich protein aggregates known as Lewy bodies (Braak et al 2003). Although 
the histopathological features of the disease have been well defined, the etiology remains 
unknown. PD is generally considered an idiopathic disease, with the majority of cases being of 
sporadic origin. Certain risk factors (aside from age) have been identified, including specific 
environmental factors such as the exposure to pesticides and certain heavy metals, rural living 
and previous head injury (Olanow and Tatton 1999, Ascherio and Schwarzschild 2016). 5-10% 
of cases have been associated to certain genes, which demonstrate both autosomal dominant 
and autosomal recessive inheritance (Klein and Westenberger 2012, Blesa and Przedborski 
2014, Kouli et al 2018).  
However, it is now known that PD is a heterogenous disease, and the pathological 
changes begin years before it is diagnosed. It is a slow, progressive, multifactorial disease, 
gradually affecting several neuroanatomical areas, caused by a complex interplay between 
environmental, lifestyle and genetic factors (Figure I.1; Kalia and Lang 2015, Poewe et al 
2017). Furthermore, due to the heterogenous and multifactorial nature of PD, patients exhibit 
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varying symptomatology and neuropathology, and there is great variation in the degree of 
responsiveness to currently available treatment options.   
1.2 Symptoms and Current Treatment Options 
PD is recognized by its distinctive primary motor symptoms: resting tremor, rigidity, 
slow movements known as bradykinesia and postural instability. However, although PD is best 
known for the symptoms that arise due to the death of DA neurons, it is known that non-
dopaminergic systems are also affected. Furthermore, PD is characterized by the 
histopathological presence of α-syn protein aggregates in both the central and peripheral 
nervous systems (CNS and PNS) (Pollanen et al 1993, Forno 1995, Spillantini et al 1998). It is 
believed that the pathological changes that accompany the formation of these protein aggregates 
not only contribute to motor dysfunction but also lead to several non-motor symptoms (Marinus 
et al 2018), which can include cognitive impairment, dementia, hallucinations, anxiety, 
Figure I.1: Parkinson’s Disease. PD is characterized by the loss of DA neurons in the SN. A) In 
healthy individuals, DA neurons project to the striatum where they release dopamine and are involved 
in motor function, and this is the population of neurons that is most affected in PD. B) Braak’s 
hypothesis of disease pathology and spread of α-synuclein in PD (Braak et al 2003).  According to this 
theory, α-synuclein inclusions begin in the lower brainstem (Braak Stage I and II) during early disease 
onset, before motor symptoms appear, although non-motor symptoms may be present. In Braak Stage 
III and IV, these inclusions infiltrate the midbrain and motor symptoms appear. In Braak Stages V and 
VI, α-synuclein aggregates spread to the limbic and neocortical brain regions in advanced stages of the 
disease (Braak et al 2003, Poewe et al 2017).  
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depression, sleep disturbances  (excessive daytime sleepiness and insomnia), constipation, 
olfactory loss and impulse control disorders (Figure I.2; Lang 2011, Marinus et al 2018). These 
non-motor symptoms can have an equally debilitating effect on the patient’s quality of life 
(Chaudhuri and Schapira 2009, Lindvall 2015a). 
Fortunately, several treatment options have been developed, based on the replacement 
of dopamine levels in the striatum. This includes administering levodopa (L-dopa), dopamine 
agonists, and/or enzyme inhibitors to reduce dopamine breakdown (including monoamine 
oxidase and catechol-O-methyl transferase inhibitors). L-dopa is currently the most effective, 
and considered the gold standard treatment (Fahn 2006, Brichta et al 2013, Lindvall 2015b). 
Furthermore, surgical interventions such as deep brain stimulation (DBS) have also been shown 
to be effective in certain patients (Lindvall and Kokaia 2009). 
However, these treatments are only effective for a limited time, as prolonged use leads 
to severe side effects. Furthermore, none of the current treatments can modify the disease, 
prevent its progression or relieve non-motor symptoms. For this reason, there is tremendous 
Figure I.2: Symptoms associated with PD. Non-motor symptoms are known to precede a clinical 
diagnosis by several years in what is called prodromal PD. The onset of motor symptoms in early-stage 
PD leads to a clinical diagnosis. As the disease progresses, both motor and non-motor symptoms 
worsen, both of which leads to further disability. Side effects of long term L-dopa use also become 
apparent, leading to fluctuations and dyskinesias. At later stages, some patients disability becomes so 
severe, they require full-time assistance from family members or caretakers (Poewe et al 2017).  
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interest in developing alternative strategies to slow down or repair the underlying process, 
especially in the form of stem cell replacement therapies. 
1.3 Current Objectives of PD Research 
 Due to the main challenges presented by PD (including late diagnosis, heterogenous 
etiology, multifactorial progression and varying degrees of patient response to treatment 
options, as described above), there is urgent need for new treatment options. To achieve this, 
one of the main objectives of PD research is a firm understanding of the pathophysiological 
changes leading to disease, in order to identify new biomarkers, allowing for an earlier 
diagnosis and the development of more preventative therapies. However, in addition to this, a 
solid understanding of the proper physiological development of DA neurons is also 
fundamental. This understanding could allow a more accurate replication of these neurons using 
stem cell technology in vitro, for cell replacement therapies, disease modeling and drug 
discovery. The focus of the present work is based on improving our current knowledge of 
proper DA neuron development, where we investigate new factors that might be important in 
this process, which could then be used to improve current protocols for stem cell replacement 
therapies and disease modeling to aid in the search of new treatments for PD.   
2. DOPAMINERGIC NEURONS  
DA neuros have been extensively studied due to their implication in PD, with the idea 
of developing cell replacement therapies as new treatment options for this disease. However, 
obtaining DA neurons that are biologically, chemically and physiologically equivalent to those 
found in the brain is a complicated process, combining and coordinating the precise expression 
of numerous signaling molecules and transcription factors. Therefore, in order to be able to 
grow fully mature and correctly functioning DA neurons in vitro, a comprehensive 
understanding of the proper physiological development of these neurons is an essential aspect 
of PD research.  
2.1 Definition  
 DA neurons are capable of releasing the catecholaminergic neurotransmitter dopamine 
and are best characterized by the presence of tyrosine hydroxylase (TH), the enzyme involved 
in the limiting step of dopamine synthesis (Arenas et al 2015). There are several dopamine 
containing neuronal cell groups found throughout the mammalian brain, with three commonly 
recognized nuclei in the ventral mesencephalon (VM, midbrain): the A8 (retrorubral area, RrF), 
A9 (substantia nigra, SN), and the A10 (ventral tegmental area, VTA) DA neuron clusters 
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(Figure I.3; Björklund and Dunnett 2007, Roeper 2013). A9 DA neurons of the SN project to 
the striatum forming the nigrostriatal pathway, where they release dopamine and are involved 
in motor function (Hegarty et al 2013). A8 and A10 neurons project to the prefrontal cortex, 
forming the mesolimbic and mesocortical systems, where they are involved in emotion and 
reward (Hegarty et al 2013, Arenas et al 2015). Although it is now known that several different 
neuronal systems are affected in PD, the cells most affected are DA neurons in the SN, which 
are responsible for the majority of motor symptoms, and therefore become a main target for cell 
replacement therapies and disease modeling.  
2.2 DA Neuron Development 
The earliest stages of DA neuron development begin with the formation of the isthmic 
organizer (IsO) and the floor plate (FP), whose combined actions initiate and coordinate 
multiple functions of proper DA neuron development, including regional identity & patterning, 
specification & proliferation of progenitors, neurogenesis and survival (Figure I.4, I.5; Arenas 
et al 2015).  
2.2.1 Early Regionalization and Patterning 
  Proper regionalization of the VM begins with formation of the IsO, which defines the 
midbrain/hindbrain boundary (MHB) based on the coordinated expression of two transcription 
Figure I.3: DA projections in the rodent brain. Several DA-containing neuronal cell groups are 
found throughout the mammalian brain. The DA neuron nuclei located in the VM include A8, A9 and 
A10. A9 dopaminergic neurons project to the striatum via the nigrostriatal pathway, whereas A8 and 
A10 DA neurons project to the prefrontal cortex via the mesolimbic and mesocortical pathways (in red)  
(Adapted from Björklund and Dunnett 2007).  
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factors: Otx2 (orthodenticle homolog 2) and Gbx2 (gastrulation brain homeobox 2). A 
concentration gradient is formed from the expression of Otx2 in the midbrain and Gbx2 in the 
hindbrain, where each transcription factor mutually represses the other, and defines the sharp 
border and proper positioning of the MHB (Wasserman et al 1997, Millet et al 1999, Rhinn and 
Brand 2001). This activates the expression of two morphogens, Wnt1 (Wingless-int1) and Fgf8 
(Fibroblast growth factor 8), but only Fgf8 is necessary and sufficient to induce the IsO 
(Martinez et al 1999). The MHB is formed based on the interaction of concentration gradients 
created by Fgf8 signaling (Arenas et al 2015). At about the same time as the formation of the 
IsO, a second patterning event takes place, which depends on the expression of Shh (Sonic 
hedgehog) to specify the most ventral region of the neural plate, forming the floor plate (FP) 
(Roelink et al 1995). The expression of Shh in the neural plate induces the expression of Foxa2, 
which is required for FP development and correct ventral patterning (Ang and Rossant 1994, 
Ang 2009). Foxa2, in turn, upregulates Shh, forming a positive-feedback loop between Shh and 
Foxa2 to regulate the proper patterning of the FP (Epstein et al 1999).  
 The importance of Shh and Fgf8 signaling (Shh for ventral FP patterning and Fgf8 for 
maintenance of IsO patterning) have made them key components in protocols for the directed 
differentiation of DA neurons in vitro (discussed below).  
 
2.2.2 Specification  
Upon the establishment of the MHB and the Shh-Foxa2 signaling network in the FP, 
Foxa2 begins to regulate the expression of two LIM homeobox transcription factors: Lmx1a 
and Lmx1b (Arenas et al 2015). Lmx1b is needed to promote the differentiation of DA neuron 
precursors (Smidt et al 2000) and Lmx1a is needed for the specification of DA neurons in the 
FP (Andersson et al 2006b). Lmx1a has been shown to upregulate Wnt1, and Wnt1 in turn 
upregulates Lmx1a and Otx2 via ß-catenin. In addition to specification of DA neurons, the 
formation of this autoregulatory loop has important functions in inhibiting alternative fates 
(Chung et al 2009). Furthermore, Lmx1a has also been shown to directly upregulate markers 
important for DA neuron differentiation: Nurr1 and Pitx3 (discussed below), which have 
important functions in the maintenance and survival of these neurons (Chung et al 2009). 
Therefore, the proper specification of DA neurons is controlled by the combined actions of the 
Shh-Foxa2 and Otx2-Wnt1-Lmx1a networks (Arenas et al 2015). 
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 2.2.3 Neurogenesis 
DA precursors are born in the ventricular zone (VZ) of the developing FP, and as they 
become post-mitotic, they begin migrating radially outwards, gradually losing progenitor 
identity as they pass through the intermediate zone (IZ). Upon reaching the mantle zone (MZ), 
these neurons migrate tangentially until they reach the SN and express mature DA identity 
markers, including TH, Nurr1 and Pitx3. This process is mainly regulated by two basic-helix-
loop-helix (bHLH) transcription factors, Neurogenin2 (Ngn2) and Mash1 (Ascl1), though only 
Ngn2 is required for DA neurogenesis (Andersson et al 2006a, Kele et al 2006). The two 
regulatory networks described above (Shh-Foxa2 and Otx2-Wnt1-Lmx1a) are direct and 
indirect regulators of Ngn2, where Foxa2 suppresses pro-neural gene inhibitors (such as Hes1 
via Ferd3l) to promote neurogenesis (Ferri et al 2007, Metzakopian et al 2012) and Lmx1a 
upregulates Ngn2 via Msx1 (Andersson et al  2006b). Although Ngn2 is expressed throughout 
the developing brain, in the context of the developing VM, cells positive for Ngn2 are 
considered DA precursors (Kele et al 2006). 
During embryonic development, it is important to keep in mind the importance of proper 
cell cycle exit of proliferating precursors to give rise to post-mitotic neuroblasts. In this context, 
Sox2, a general marker of neural precursors in the developing brain, has been shown to interact 
with Ngn2 to drive cell cycle exit and promote neurogenesis (Graham et al 2003).  In the 
developing VM, cells expressing the marker Sox2 make up the population of proliferating 
precursors in the VZ, and Ngn2 has been shown to be co-expressed in some Sox2-expressing 
Figure I.4: Neurogenesis in the developing VM. DA neurons are born in the VZ (yellow cells), where 
they are considered mitotic precursors, expressing markers such as Sox2. As these precursors begin to 
migrate through the IZ (orange cells), they become post-mitotic precursors expressing markers such as 
Ngn2 and some Nurr1. DA neurons are considered mature upon reaching the MZ (blue cells) where 
they express markers such as TH, Nurr1 and Pitx3. Early markers important for regionalization of the 
FP such as Foxa2 and specification of DA precursors such as Lmx1a are expressed in all three zones 
(yellow, orange and blue cells) throughout development and into adulthood. 
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proliferating precursors. As these cells exit the cell cycle, Ngn2 expressing cells that have lost 
Sox2 expression make up the IZ, and these cells continue migrating, gradually gaining the 
expression of mature DA neuron markers such as Nurr1 and TH. The coordinated expression 
of these markers indicates the importance of proper spatiotemporal control during DA 
development, although the exact interaction between Sox2 and Ngn2 remains poorly  
understood (Kele et al 2006). 
 
Figure I.5: Network of known factors controlling DA neuron development. DA neuron 
development begins with the formation of the MHB, controlled by Otx2 (yellow area) and the IsO (pink 
and green area), which establishes the two signaling centers that later secrete Fgf8 and Shh. Shh forms 
an autoregulatory loop with Foxa2 (pink area) and is responsible for the proper regionalization and 
patterning of the FP. Otx2 also forms a  regulatory loop with Wnt1 and Lmx1a to specify DA neuron 
precursors (blue area). The collaborative actions of the Shh-Foxa2 and Otx2-Wnt1-Lmx1a networks 
control the expression of Ngn2 (purple area) to initiate neurogenesis of DA neuron precursors. 
Neurogenesis of DA neurons takes place as precursors migrate through the VM to their final destination 
in the SN, and express the mature DA neuron markers TH, Nurr1 and Pitx3, which become important 
in maintaining phenotype stability and functionality (Arenas et al 2015).  
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 2.2.4 Differentiation and Survival  
  After neurogenesis, the post-mitotic precursors located in the IZ begin to differentiate 
into DA neurons, which continue to migrate until they reach their final destination in the MZ 
(Arenas et al 2015). Nurr1 is the first post-mitotic marker of DA precursors, which is necessary 
for the survival of DA neuroblasts, proper neurotransmitter identity and maintenance of a 
mature DA neuron phenotype (Zetterström et al 1997, Kadkhodaei et al 2009). Of particular 
importance, Nurr1 has been shown to induce the expression of TH, the gold-standard marker 
for DA neurons, and is the first mature marker that appears in the developing VM (Smits et al 
2003). Another important marker of mature DA neurons is Pitx3, which appears to be 
independent of the Nurr1-TH cascade (Smidt et al 2000). Pitx3 is required for terminal DA 
neuron differentiation and phenotype maintenance (Li et al 2009). 
 Furthermore, both Pitx3 and Nurr1 have been shown to have important functions in 
acquiring phenotypic markers of DA functionality such as dopamine transporter (DAT), 
vesicular monoamine transporter 2 (Vmat2), dopamine D2 receptor (Drd2) and glial-cell line 
derived neurotrophic factor (Gdnf) (Saucedo-Cardenas et al 1998, Jacobs et al 2009, 
Kadkhodaei et al 2009, Arenas et al 2015).  
 Although a great deal is known about factors important and necessary for the proper 
development of these neurons, it remains a highly complex and complicated process. This is 
caused, in part, by the fact that there are most likely several other factors involved that have yet 
to be described. Previous evidence supports the idea that the cell cycle protein p27Kip1 (p27) 
has important functions in driving neurogenesis, which was described for cortical neurons 
(Nguyen et al 2006). Furthermore, it was also shown that p27 overexpression could promote 
the differentiation of VM neurospheres to DA neurons (Sacchetti et al 2009).  
3. P27KIP1 AND DOPAMINERGIC NEURONS 
p27 is a cyclin/cyclin-dependent kinase inhibitor (CKI) belonging to the Cip/Kip family 
of proteins. p27 and its family members p21Cip1(p21)  and p57Kip2 (p57) share a conserved N-
terminal domain that facilitates binding to cyclin and cyclin dependent kinase (CDK) 
complexes (Besson et al 2008). These conserved structures make up the kinase inhibitory 
domains (KID), which include three subdomains: the cyclin-binding subdomain (D1), the 
CDK-binding subdomain (D2), and a linker domain (LH) that links the D1 and D2 subdomains 
(Lacy et al 2004, Otieno et al 2011, Bachs et al 2018). The inhibitory action of CKIs occurs 
when a portion of the D2 subdomain is introduced into the catalytic center of CDKs, directly 
competing with and inhibiting ATP binding (Russo et al 1996). Interestingly, the D1 and D2 
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subdomains are mostly unfolded in isolated p27, but quickly fold upon the association with 
CDKs, and the KID is known to contain a nuclear export signal (NES) (Bachs et al 2018).  
Despite these conserved regions, CKIs are generally considered intrinsically disordered 
proteins due to their lack of tertiary structure in isolation (Dyson and Wright 2005, Huang et al 
2015). The C-terminal domain, in particular, is an intrinsically disordered region which 
includes a nuclear localization signal (NLS) and differences observed in the remainder of their 
sequences indicate that p27, p21 and p57 may each have individual functions (Besson et al 
2008).  
p27 is best known for its cell cycle-dependent functions and promoting cell cycle exit. 
However, in recent years it has been demonstrated that p27 also has cell-cycle independent 
functions, which implicates this protein in a broad range of processes, including neurogenesis. 
Currently, no link between p27 and PD has been described, but it has been suggested that p27 
may regulate α-syn expression, and our results show an important function of p27 in the 
development of DA neurons.  
3.1 Cell-Cycle Dependent Functions of p27 
Cyclins and CDKs are a group of proteins whose coordinated activities are involved in 
the regulation of the cell cycle (Sherr and Roberts 2004). The cell cycle is composed of 4 phases, 
including: G1 (when the cell is preparing for DNA synthesis), S (when the cell is actively 
synthesizing DNA), G2 (when the cell is preparing for mitosis) and M (mitosis, or cell division) 
(Schafer 1998). Progression through G1 phase is dependent on Cyclin D-Cdk4/6 complexes, 
while Cyclin E/A-Cdk2 signals for the G1/S transition. Cyclins B combined with Cdk1 are 
required for the advancement of G2/M (Sherr and Roberts 1999; Bilodeau et al 2009). 
p27 is best known for its function in promoting cell cycle exit, which it primarily does 
by binding to the catalytic cleft of Cyclin E/A-Cdk2 complexes, inhibiting ATP binding and 
the phosphorylation of retinoblastoma (Rb) proteins. In a hypo-phosphorylated state, Rb 
remains bound to E2F, thereby preventing E2F-mediated transcription of genes necessary to 
drive the cell cycle (Ludlow et al 1990). The control of p27 in the cell cycle is further supported 
by evidence suggesting that D-type cyclins sequester p27, preventing p27 from inhibiting 
Cyclin E/A-Cdk2 complexes, leading to phosphorylated Rb and E2F-mediated transcription 
that promotes the G1/S transition (Sherr and Roberts 1999). Furthermore, it has been shown 
that in mitogen rich conditions, p27 stabilizes Cyclin D-Cdk4/6 complexes, promoting G1 
phase progression, whereas in mitogen starved conditions, these complexes disassemble, 
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preventing Cyclin D-Cdk4/6 from promoting cell cycle progression, leaving p27 free to 
associate with and inhibit Cyclin E/A-Cdk2 complexes (Figure I.6; Sherr and Roberts 1999).  
3.2 Cell-Cycle Independent Functions of p27 
As mentioned before, p27 is classified as an intrinsically disordered protein, and in 
addition to its function in regulating the cell cycle, important roles of p27 have been found 
linked to apoptosis, transcriptional regulation, cell fate determination, cell migration and 
cytoskeletal dynamics (Besson et al 2008). p27 has been found to regulate processes directly 
related to neurogenesis as well, such as promoting the differentiation and radial migration of 
cortical projection neurons, where neural differentiation was promoted by the stabilization of 
Ngn2 at the N-terminal half of p27, and neural migration was promoted by blocking RhoA 
activity at the C-terminal half (Nguyen et al 2006). p27 has been shown to directly repress Sox2 
(a neural precursor in the context of DA neuron development) during stem cell differentiation, 
indicating a possible role of p27 in DA neuron differentiation (Li et al 2012) and it has been 
demonstrated that p27 promotes tangential migration through its association to microtubules 
that promote polymerization in extending neurites (Godin et al 2012). In recent years, increased 
interest in p27 as a transcriptional regulator has shown important functions of p27 in association 
with several different transcription factors to promote gene expression important in functions 
such as: promoting the cell cycle (via p130-E2F), neurogenesis (via Ngn2), muscle 
differentiation (via MyoD) and to promote cell adhesion, ion transport and cell signaling (via 
both PCAF and Pax5) (Bachs et al 2018). Recently, loss of p27 was associated with increased 
Figure I.6: Cell cycle and inhibition by p27. The cell cycle is composed of 4 phases (G1, S, G2 and 
M) controlled by the coordinated expression of cyclins and CDKs. p27 inhibits the progression from 
G1 to S by binding to the catalytic cleft of Cyclin E/A-Cdk2 complexes, preventing its ability to 
phosphorylate Rb complexes. Rb associated to E2F renders E2F unable to mediate the transcription 
of genes controlling cell cycle progression.  
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α-syn expression in the cerebellum of p27 KO mice, implicating p27 as a possible participant 
in the induction of PD (Gallastegui et al 2018). 
3.3 Transcriptional and post-translational regulation of p27 
 p27 is ubiquitously expressed and is maximal in quiescent cells (Chu et al 2007). Its 
expression is regulated by both transcriptional and post-translational processes, and certain 
transcriptional regulators have been identified that can either activate or repress the 
transcription of p27 (Bachs et al 2018). However, p27 is mainly regulated by controlling its 
degradation, which is primarily stimulated by phosphorylation at specific threonine and serine 
sites, marking it for ubiquitin-dependent proteolysis (Shirane et al 1999, Hnit et al 2015). The 
most studied process of p27 regulation is the polyubiquitylation and subsequent degradation by 
the SCFSKP2-complex, specifically S-phase kinase associated protein 1 (Skp1) and S-phase 
kinase associated protein 2 (Skp2). Cyclin E/A-Cdk2 complexes, the same complexes inhibited 
by p27, are known to phosphorylate p27 at T187, targeting it for SCFSKP2-mediated degradation, 
and thereby promoting cell-cycle progression (Nakayama and Nakayama 2006, Chu et al 2008, 
Teixeira and Reed 2013). p27 degradation can also take place without T187 phosphorylation, 
mediated by both Skp2 dependent and independent pathways (Hara et al 2001, Kossatz et al 
2001, Chu et al 2007). Furthermore, phosphorylation of p27 at T74, T88, and T89 has been 
shown to greatly decrease its ability to inhibit Cyclin E/A-Cdk2 complexes, thereby reducing 
its cell cycle inhibitory function (Besson et al 2008), further indicating the importance of post-
translational modifications in the regulation of p27 function.  
3.4 Subcellular localization of p27 
The subcellular localization of p27 has important implications. In the nucleus, p27 can 
act as a transcriptional regulator and can be directly involved in gene expression, as briefly 
described above (Sherr and Roberts 1999, Bachs et al 2018). Cytoplasmic localization tends to 
be associated with dysregulation and degradation of the protein, which may be implicated in 
pathologies such as cancer and neurodegenerative diseases (Besson et al 2008, Bachs et al 
2018). The implication of p27 in cancer has been very well described, and decreased levels of 
p27 or a cytoplasmic localization has been associated with higher malignancy and poorer 
prognostic outcome (Chu et al 2008, Lee and Kim 2009, De Almeida et al 2015, Yang and Al-
Hendy 2018). 
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3.5 Application of p27 in neurodegeneration and PD 
 p27 has been identified as an important biological regulator of neuronal differentiation 
(Ngyuen et al 2006, Biçer et al 2017, Perearnau et al 2017), and several transcriptional programs 
have been shown to be related to different neurodegenerative diseases, including PD (Bachs et 
al 2018). Furthermore, p27 has been shown to repress α-syn expression in a mechanism 
involving p130-E2F, suggesting an important implication of p27 in the etiology of the disease 
(Gallastegui et al 2018). The main focus of this work is to elucidate the possible role of p27 on 
DA neurogenesis. In vivo, we are investigating the differences in the developing midbrain of 
p27-deficient and wild-type mice. In vitro, we are comparing the effects of p27 deficient, p27-
recovery and p27-overexpressing pluripotent stem cells. This knowledge could expand our 
understanding of DA neuron development, which would be of interest for improving current 
protocols of DA neuron differentiation in vitro from different types of stem cells and help 
develop a reliable source of these cells for clinical use in cell replacement therapies for the 
treatment of PD.  
4. STEM CELLS AND THEIR APPLICATION IN PD 
 Stem cells are unspecialized cells with the ability to self-renew. In specific conditions, 
these cells begin to differentiate, and depending on the context, give rise to more specialized 
cell types and can be classified into different types based on their differentiation potential. 
Pluripotent stem cells (PSCs) are cells that can give rise to any cell of the organism, from the 
three germ layers (endoderm, mesoderm and ectoderm). Multipotent stem cells (MSCs) are 
more specialized cells that can give rise to all the cells of a given lineage (for example, neural 
stem cells can give rise to all the cells of the nervous system). Unipotent stem cells (USCs) are 
the most specialized stem cell which can give rise to cells of a certain tissue. Due to their 
properties, PSCs and MSCs are currently considered the best sources for developing new 
treatment options for PD (reviewed in Palmer and Liste 2016, Palmer et al 2018). 
4.1 Stem Cell Technology and PD 
 In PD research, the two main types of stem cells currently being investigated as potential 
treatment options are PSCs and MSCs. The type of PCSs being used are embryonic stem cells 
(ESCs) and induced PSCs (iPSCs), while the type of MSCs include neural stem cells (NSCs) 
and mesenchymal stem cells (MeSCs).  DA neurons have been efficiently derived from ESCs 
(Chambers et al 2009, Kriks et al 2011, Kirkeby et al 2012, Grealish et al 2014), iPSCs  and 
NSCs, (Villa et al 2009, Courtois et al 2010) while MeSCs are currently being investigated for 
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their potential neuroprotective qualities (Glavaski-Joksimovic and Bohn 2013, Palmer et al 
2018). In this work, we focus on the use of ESCs, iPSCs and NSCs. 
  
4.1.1 Embryonic Stem Cells 
   ESCs are naturally pluripotent cells obtained from the inner cell mass of the blastocyst 
that forms about one week after fertilization of the human embryo (Thomson et al 1998). The 
discovery of these cells offered a new approach to biomedical research and regenerative 
medicine, and provided new ways to overcome issues of donor tissue shortage and implant 
rejection, as well as the possibility to obtain and purify specific cell types to be used for cell 
Figure I.7: Application of iPCSs in disease modeling, drug discovery and cell therapy. Adult 
somatic cells can be reprogrammed using specific genes to induce pluripotency. Once cells express these 
genes endogenously, they can be used to obtain any cell from the three germ layers. iPSCs have 
incredible value and potential, as they can be sourced from adult somatic cells with no associated ethical 
issues. Strategies using integrative vectors can be used for disease modeling and drug discovery, while 
non-integrative strategies are also being explored for their potential use as cell replacement therapies 
(Adapted from Revilla et al 2015). 
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replacement therapies, disease modeling and drug screening (He et al 2003). However, despite 
their promise and potential, the main limitation of their widespread use is the high ethical 
concern associated with their isolation from aborted embryos. For this reason, finding a new 
source of PSCs was intensely researched for almost two decades.   
  
4.1.2 Induced Pluripotent Stem Cells  
 In 2006, Takahashi and Yamanaka made a remarkable breakthrough in stem cell 
research with the discovery of what we now know as iPCSs. These cells were adult somatic 
cells that, upon the addition of the four factors Oct4, Sox2, Klf4 and c-myc, Yamanaka and his 
team were able to reprogram the differentiated state of these adult cell, reverse their 
specification and return them to a pluripotent state (Figure I.7; Takahashi and Yamanaka 2006, 
Takahashi et al 2007, Yu et al 2007). These new cells showed characteristics almost identical 
to ESCs, including: cell morphology, the expression of pluripotency markers, epigenetic 
changes, ability to generate cells of all three germ layers in vitro and in vivo (by forming 
teratomas) and the ability to generate viable chimeras (Takahashi and Yamanaka 2006).  
Today, a variety of strategies and protocols have been developed based on the basic 
concept of differentiating pluripotent stem cells to neuroprogenitor cells, expanding the 
population and finally guiding differentiation to DA neurons with specific factors implicated in 
proper DA development (Freed et al 2011, Kirkeby et al 2012, Grealish et al 2014). The most 
effective protocols involve early dual SMAD inhibition (Chambers et al 2009), high levels of 
Shh for early induction of FP specification (Fasano et al 2010), GSK3-ß inhibition (Kriks et al 
2011) and the addition of certain transcription factors such as Lmx1a (Friling et al 2009) and 
Wnts (Andersson et al 2013). 
However, an optimized differentiation protocol for the development of safe and viable 
dopaminergic neurons for large-scale cell replacement clinical application is still lacking. The 
work in our lab is aimed towards improving the development of such protocols, by studying 
novel factors that might be important for proper DA neuron development. 
 
4.1.3 Neural Stem Cells 
NSCs are a type of multipotent stem cells frequently used in PD research. These cells 
are more differentiated than PSCs and have a more limited differentiation capacity. Specifically, 
NSCs give rise to precursors that grow and differentiate into cells making up neural tissue, 
including neurons and glia. NCSs can be acquired from the fetal, neonatal and adult brain or 
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from the directed differentiation of pluripotent stem cells. (Martínez-Morales and Liste 2012). 
Neural precursor cells obtained from the human VM are considered the best candidates for cell 
therapies in PD, but as mentioned above, their widespread use for large scale clinical application 
is limited. Apart from high ethical concerns, these cells have unstable phenotypes, present 
reduced growth potential, and survive poorly after grafting (Villa et al 2009, Martínez-Serrano 
and Liste 2010, Martínez-Morales and Liste 2012). 
4.2 Stem Cell Therapy for PD in Clinical Trials 
Several open-label clinical trials involving the intrastriatal transplantation of human 
fetal mesencephalic tissue has provided proof of principle that stem cell replacement therapy 
can be a clinically competitive treatment option for PD (Barker et al 2013, Palmer et al 2016, 
Björklund and Lindvall 2017). These trials showed that transplanted tissue is able to generate 
DA neurons capable of re-innervating the denervated striatum, restoring striatal dopamine 
Figure I.8: Stem cell therapies in PD. PSCs such as ESCs and iPSCs can be used to obtain DA 
neurons, by first inducing a neural identity and later specifying these cells towards a DA neuron 
phenotype. NSCs sourced from the fetal brain are currently the best option for cell replacement 
therapies in PD, and can be administered as cell suspensions or as solid grafts. However, high ethical 
concerns with using fetal tissue limits their widespread clinical use. (Adapted from Palmer et al 2018). 
39 
release and providing significant symptomatic relief in some patients (Figure I.8; Lindvall et al 
1989, Lindvall et al 1990, Freed et al 1992, Spencer et al 1992, Piccini et al 2000, Kefalopoulou 
et al 2014). The success and excitement that emanated from these initial trials led the NIH to 
approve two double-blind, placebo-controlled studies (Freed et al 2001, Olanow et al 2003). 
Neither of these trials, however, were successful in meeting their primary end-point, and the 
inconsistent results, both between and within trials, has made it difficult for further 
transplantation trials to be approved. Currently, the TRANSEURO trial funded by the European 
Union is ongoing, whose main objective is to standardize transplant procedures using fetal 
tissue in order to create a template protocol for clinical trials, and hopefully prove the efficacy 
of such treatment options for PD with improved patient selection, tissue preparation, tissue 
delivery and immunosuppressive treatments (transeuro.org.uk).  
However, the use of fetal tissue is limited for large-scale clinical use, due to technical 
issues with tissue procurement and high ethical concerns. For this reason, a more reliable source 
of cells for replacement therapies must be found, with the goal of developing a uniform source 
of dopaminergic neurons (discussed above). 
4.3 Advantages and Challenges 
The discovery of stem cells has revolutionized biomedical research, as it has provided 
us a tool that can be manipulated in an unlimited number of ways to study specific disease 
processes, test new drugs and to investigate new therapeutic alternatives, based on the use of 
these cells to replace those damaged or lost due to pathological processes. 
However, before stem cells can be approved for clinical applications in PD, they must 
first meet several strict safety requirements. A general target of using stem cell technology to 
obtain DA neurons is to obtain cells equivalent to those of human VM.  When transplanted, 
these cells must be able to survive, integrate into the host circuitry by re-innervating the striatum 
without tumor formation or evoking an immune response. Furthermore, they need to 
significantly improve motor symptoms, not cause side effects including the development of 
involuntary movements such as dyskinesias (Lindvall and Kokaia 2009, Barker 2014, Lindvall 
2015b). 
Although great advancements have been made in the field of stem cell therapies for PD 
and in our knowledge of fundamental processes involved in DA neuron development, there is 
still no optimized protocol for the development of these neurons in vitro for large scale clinical 
applications. The focus of this thesis has been studying novel factors involved in DA neuron 
development, with the general goal of contributing to the improvement of current protocols, by 
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increasing homogeneity of DA neuron production. Based on previous results, including one 
study showing that increased levels of p27 in VM neurospheres favored the differentiation of 
these cells (Sacchetti et al 2009), this work has studied the effects this cell cycle protein has on 
the development and differentiation of DA neurons, both in vivo and in vitro, whose effects in 






































































Our general objective is to improve the knowledge of DA neuron development, which 
could assist in improving the differentiation of these neurons in vitro for possible future 
therapies to help treat PD.  
 
 
The presented work had two main objectives: 1) to study the effects of p27 deficiency on the 
development of DA neurons in vivo and 2) develop cellular models to study the effects of p27 
on the differentiation of DA neurons in vitro. 
 
In order to study these objectives in detail, the specific objectives were as follows: 
 
1.) Establish an expression pattern for p27 in the developing embryonic mouse midbrain 
in relation to factors important for proper DA neuron development. 
 
2.) Study the effects of p27 deficiency on different stages of embryonic mouse midbrain 
development. 
 
3.) Study possible mechanisms to explain the observed effects of p27 deficiency in vivo. 
 
4.) Study the effects of p27 deficiency on VM primary cultures. 
 
5.) Generate and establish a cell line of mouse induced pluripotent stem cells (miPSC) 
from p27 deficient and p27 control mouse embryonic fibroblasts to study the effects of 
p27 deficiency on DA neuron development in vitro. 
 
6.) Generate and establish a cell line of miPSCs to study the re-introduction of p27 into 
p27 deficient cells (from here on “p27 recovery”) and its effect on DA neuron 
development in vitro. 
 
7.) Generate and establish a cell line of miPSCs to study p27 overexpression in p27 


























1. IN VIVO 
1.1 Ethics statement 
Mice were housed, bred and treated in accordance with protocols approved by local 
ethics committees at the Instituto de Salud Carlos III (CBA-PA-97-2010). p27 null mice were 
obtained as previously described (Fero et al 1996) and animal work was done in accordance 
with national and European legislation regarding the use of laboratory animals.  
1.2 Genotyping 
Standard PCR analysis was performed to confirm genotypes of mice born to maintain 
the p27-null mouse line. DNA was extracted from tail samples by first adding 2M NaOH + 
0.5M EDTA in H2O, and placed in a thermal block set to 95˚C for 1 hour. Then, 1M Tris-HCl 
(pH 7.5) in H2O was added, samples were centrifuged at 2000 rpm for 10 minutes (or until a 
pellet formed) and the supernatant was recovered. PCR was carried out using specifically 
designed primers (Table 1) in a SimpliAmpTM Thermal Cycler (Applied Biosystems), with the 
following optimized program: 1 cycle of 94˚C for 3 minutes, 40 cycles of 94˚C for 30 seconds, 
59˚C for 30 seconds and 72˚C for 1 minute, 1 cycle of 72˚C for 10 minutes and finally cooled 
to a holding temperature of 4˚C. The samples were then subjected to electrophoresis on a 1.5% 
Agarose (Lonza) gel at 80V. p27+/- females were mated with p27+/- males to generate p27-/- 
embryos, and PCR was also needed to confirm the genotypes of embryos obtained for analysis. 
For this purpose, DNA was extracted from embryo tissue by adding 2M NaOH + 0.5M EDTA 
in H2O, then placed in a thermal block set to 95˚C, and tissue dissociation was checked every 
10 minutes. Once the tissue had dissociated, 1M Tris-HCl (pH 7.5) in H2O was added, samples 
were centrifuged at 2000 rpm for 10 minutes (or until a pellet formed) and the supernatant was 
recovered. The PCR was then carried out as described above.  
 
 
Table 1: Primers used for genotyping  















1.3 Embryo brain section preparation 
For analysis of embryonic brains, mice were mated overnight, and at noon the following 
day, observed plugs were considered E0.5. Mothers were sacrificed at days equivalent to 
embryonic ages E11.5, E12.5, E13.5 and E14.5 at which time embryos were dissected out of 
the uterine horns and cleaned with cold Phosphate buffered saline (PBS) 1X. Brains were left 
in the developing skull to preserve morphology, and fixed in 4% paraformaldehyde (PFA) for 
2 hours. Brains were then washed 3 x 10 minutes in PBS 1X and transferred to 30% sucrose for 
at least 24 hours. Finally, brains were included in a solution consisting of 15% sucrose + 7.5% 
gelatin, and frozen at -80ºC with isopentane (Sigma) until used. 15μm serial coronal brain 
sections were obtained on a cryostat (Leica) and mounted on Superfrost Ultra Plus® 
microscope slides (Thermo Scientific). Heterozygous (p27+/-) females were crossed with 
heterozygous males to generate p27-/- embryos, which were carefully genotyped as described 
above. p27+/+ embryos were used as controls.  
 
2. IN VITRO: PRIMARY CULTURES 
2.1 Mouse Embryonic Fibroblast (MEF) extraction 
 Time mated females were sacrificed at days equivalent to embryonic ages E13.5 or 
E14.5, when embryos were extracted from the uterine horns and cleaned with cold PBS 1X. 
Internal organs and heads were removed and saved for genotyping. The remaining skin was 
cleaned and rinsed, and manually dissociated with the help of a sterile razor blade. Each embryo 
was added to a separate 15mL centrifuge tubes containing 500µL trypsin-EDTA 0.25% 
(Thermo Scientific) and left for 30 minutes at 37ºC. Trypsin was deactivated by adding 2mL of 
MEF medium (Table 2), and the cells were resuspended until completely dissociated. The cells 
were then centrifuged for 2 minutes at 900 rpm and the supernatant removed. 2mL of fresh 
MEF medium was added, and the process of centrifugation was repeated 2 more times. The last 
centrifugation was left for 5 minutes at 900 rpm. Cells were then seeded at a density of one 
embryo per 60-120cm2 depending on the size of the pellet and maintained in an incubator set 
to 37ºC and 5% CO2. MEFs that were not needed were frozen at -80ºC for future use and only 
early-passage MEFs (less than 5 passages) were used for our experiments. 
2.2 VM primary culture  
Primary cultures of VM precursors were dissected directly from the E13.5 embryonic brain 
with the aid of a magnifier under sterile conditions in a horizontal laminar-flow hood. In the 
developing rodent brain, the midbrain is a tube recognized by it characteristic curve behind the 
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cortex, which was removed and placed in cold, sterile PBS 1X with 0.05% glucose. Straight 
surgical micro-scissors were then used to remove the upper curve of the midbrain, 
corresponding to the dorsal mesencephalon (DM). The bottom curve, corresponding to the VM 
was flattened and recognized by its “butterfly” shape, from which the edges were trimmed with 
a sterile razor blade, if necessary. Each dissected VM was kept separate and manually 
dissociated. Bodies were saved for genotyping. Cells were seeded on poly-L-lysine (10µg/mL, 
Sigma) and laminin (1.5µg/mL, Sigma) treated plastic culture plates. In the case of using glass 
cover slips, these were treated with 30µg/mL poly-L-lysine and 1.5µg/mL laminin. 150,000 
cells were initially seeded in 30µL drops for 15 minutes to promote adhesion, and later 
maintained in a chemically defined medium (N2:B27 medium) consisting of N2 medium (Table 
3) in a 1:1 ratio with NB:B27 medium (Table 4) supplemented with Shh (200ng/µL, Peprotech), 
Fgf8 (25ng/µL, Peprotech) and Fgf2 (10ng/µL, Preprotech) for 3 days and maintained in an 
incubator set to 37ºC and 5% CO2.  
 
Table 2: MEF Medium 
 
 
Table 3: N2 Medium 
Component Final Concentration Source Reference 
 
DMEM:F12 with GlutaMAX-I 
20% AlbuMAX in DMEM:F12 
1M HEPES 































Table 4: NB:B27 Medium 






















Component Final Concentration Source Reference 
 
DMEM* 
Fetal Bovine Serum (FBS) 


















*Non-essential amino acids 
**Penicillin/Streptomycin *Dulbecco’s modified eagle medium 
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3. IN VITRO: CELL LINES 
3.1 Cells and culture conditions  
 3.1.1 PA6 stromal cells 
 PA6 mouse stromal cells were maintained as monolayer cultures in PA6 medium (Table 
5) on plates pre-treated with 0.1% gelatin. For neural induction, they were inactivated with 
Mitomycin (Roche) at 1µg/mL overnight and seeded at a density of 50 x 103 cell/cm2. Cells 
were maintained in an incubator set to 37ºC and 5% CO2. 
 
Table 5: PA6 medium 























 3.1.2 mESCs and miPSCs 
 mESCs and miPSCs were grown as monolayer cultures in SRM medium (Table 6) 
supplemented with Leukemia inhibitory factor (Lif, 1000U/mL; Millipore). Cells were allowed 
to grow until ~80% confluence, at which time they would be passed. Cells were grown in 
culture plates pre-treated with 0.1% gelatin and maintained in an incubator set to 37ºC and 5% 
CO2. 
 
Table 6: SRM Medium 
Component Final Concentration Source Reference 
 
KO-DMEM* 
Serum replacement (SR) 



























3.2 Reprogramming MEFs to miPSCs 
After extracting MEFs and properly genotyping the embryos, mouse iPSC p27+/+ 
(miPSC WT) and mouse iPSC p27-/- (miPSC p27KO) cells were reprogrammed from MEFs 
by retroviral infection (kindly provided by Dr. Han Li and Manuel Serrano, Li et al 2012) or 
reprogrammed using the CoMIP plasmid according to the diagram in Figure M.1. CoMIP is an 
*Knock Out-DMEM 
*Minimum essential medium with α-modification  
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optimized mini-intronic plasmid containing the four pluripotency genes Sox2, Oct4, Klf4 and 
c-Myc allowing for efficient reprogramming after a single transfection (Diecke et al 2015). 5 x 
106 cells were co-nucleofected with the CoMIP and pMax-GFP plasmids using the A-23 
program of the Amaxa Nucleofector system (Lonza), according to the manufacturers 
instruction. After nucleofection, MEFs were seeded in MEF medium (Table 2) supplemented 
with ascorbic acid (AA; 50µg/mL; Sigma) and sodium butyrate (SB; 0,2 mM; Tocris). Two 
days after nucleofection, the medium was changed to SRM medium (Table 6) supplemented 
with Lif (1000U/mL), AA (50µg/mL) and SB (0,2 mM). Once colonies began to form, cells 
were passed and left in SRM medium supplemented with Lif (1000U/mL). 
MEFs from p27-/- embryos E13.5(1) and E13.5(9) were reprogrammed to become 
miPSC p27KO(1) and miPSC p27KO(9), respectively. MEFs from p27+/+ embryos were 
reprogrammed to become miPSC WT controls.  
 
3.3 Nucleofection with pBabep27  
miPSC p27KOp27 recovery, R1 mESCp27 overexpression and miPSC WTp27 overexpression cells were 
obtained by nucleofection with the plasmids pBabe-p27Kip1-puromycin (Li et al 2012) and 
pMax-GFP into 2 x 106 cells using the A-13 program of the Amaxa Nucleofector system 
(Lonza), according to the manufacturer’s instruction. The empty vector pBabe-puromycin was 
used to obtain control cells. Cells were subject to selection for two weeks with puromycin 
(2µg/mL medium, Apollo Scientific Limited) to eliminate non-resistant cells, forming a 
heterogeneous cell line, according to the diagram in Figure M.2. A limiting dilution protocol 
was then followed to obtain homogenous cell populations, from which several clones were 
obtained and at least two clones were selected for each experiment. Once selected, these cells 
were maintained in ordinary SRM medium (Table 6) supplemented with Lif (1000U/mL).  
Figure M.1: Reprogramming Protocol. Diagram representing the reprogramming protocol 
followed. MEFs were isolated from p27+/+ and p27-/- embryos and subjected to nucleofection with 
the CoMIP plasmid until stem cell colonies began to appear.  
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3.4 Nucleofection with pCX-NeuroD1  
miPSC p27KONeuroD1 cells were obtained by nucleofection with the plasmids pCX-
NeuroD1-neomycin (Boutin et al 2010) and pMax-GFP into 2 x 106 cells using the A-13 
program of the Amaxa Nucleofector system (Lonza), according to the manufacturer’s 
instruction. The empty vector pCX-neomycin was used to obtain control cells. Cells were 
subject to selection for two weeks with neomycin (150µg/mL medium, Gibco) forming a 
heterogenous cell line, according to the diagram in Figure M.2. A limiting dilution protocol was 
followed as described above, and two p27KONeuroD1 clones were chosen. After selection, these 










3.5 Embryoid Body formation and differentiation 
Embryoid bodies (EBs) were formed by seeding 500 cells in 20µL drops consisting of 
SRM medium (Table 6) and left in suspension for 3 days. On day 3, EBs were transferred 
individually to plates pre-treated with 0.1% gelatin for at least 30 minutes. Once transferred, 
EBs were left in SRM medium, an un-specified differentiation medium, in order to promote 
spontaneous differentiation and confirm the differentiation potential of our iPSCs.  
3.6 Differentiation of DA neurons 
The differentiation of miPSCs to DA neurons was achieved by adapting the protocol 
described by Barberi et al 2003, consisting of SRM medium (Table 6) supplemented with Shh 
(200ng/µL, Peprotech) and Fgf8 (25ng/µL, Peprotech), N2 medium (Table 3) supplemented 
with Shh (200ng/µL, Peprotech), Fgf8 (25ng/µL, Peprotech) and Fgf2 (10ng/µL, Preprotech) 
and N2 medium (Table 3) supplemented with AA (100uM), BDNF (Brain derived neurotrophic 
factor; 20ng/µL) and GDNF (20ng/µL) according to the timeline presented in Figure M.3. Cells 
Figure M.2: Nucleofection Protocol. Diagram representing the nucleofection protocol followed. 
miPSCs were nucleofected with the appropriate plasmids, and subject to selection with the 
corresponding antibiotic treatment (puromycin or neomycin). After selection, individual colonies were 
isolated .  
α D0- D14-30- 
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were seeded at low density (60 cells/cm2) in order to promote the formation of colonies, and 








4. EXPERIMENTAL TECHNIQUES 
4.1 Bacterial transformation for plasmid expansion and purification  
1 vial of TOP10 competent bacterial cells (Thermo Scientific) was added to previously 
chilled, individual polystyrene tubes and maintained on ice for 15 minutes. 50ng of plasmid 
was added to each tube and left on ice for another 15 minutes. All tubes were then subject to 
thermic shock by being placed in a water bath set to 42ºC for 45 seconds to introduce the 
plasmid into the bacteria. After 45 seconds, tubes were placed on ice for 2 minutes. Lysogeny 
broth (LB) agar previously heated to room temperature was added to each tube for a final 
volume of 1mL. Tubes were then incubated with agitation for 1 hour at 37ºC. Each tube was 
then seeded on LB agar plates containing ampicillin (50µg/mL) at a concentration of 1/10 
(100µL of bacterial mixture) or 9/10 (900µL of bacterial mixture centrifuged to eliminate 
excess supernatant) and left at 37ºC for 24 hours. The following day individual colonies were 
isolated and placed in 50mL centrifuge tubes containing 6mL LB agar with ampicillin (50-
100µg/mL). Tubes were then incubated with agitation at 37ºC for 24 hours. The following day, 
plasmids were isolated using the Plasmid Mini Kit (Qiagen) according to the manufacturer’s 
instruction.  
4.2 Immunohistochemistry (IHC) and image analysis 
Frozen microscope slides were allowed to dry at room temperature for at least 1 hour, 
de-gelatinized at 37˚C for 20 minutes and placed in a humidity chamber. Sections were then 
washed with PBS 1X, left in blocking solution (Table 7) at room temperature for 1 hour and 
incubated with primary antibody diluted in blocking solution overnight at 4˚C. After removal 
of the primary antibody, slides were rinsed in washing solution (Table 8) and incubated with 
the corresponding secondary antibody diluted in blocking solution for 2 hours at room 
temperature. All primary antibodies used are listed in Table 9 and secondary antibodies are 
Figure M.3: PA6 Differentiation Protocol. Diagram representing the differentiation protocol 
adapted from Barberi et al 2003.  
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listed in Table 10.  After washing with PBS 1X, the slides were incubated with Hoechst 33258 
(0.2µg/mL, Invitrogen) diluted in PBS 1X for 10 minutes and mounted using Mowiol (Sigma) 
with DAPCO (Sigma) to preserve fluorescence. A confocal microscope (Leica SP5) was used 
for image capture. Total number positive cells for each marker were counted using Adobe 
Photoshop CC, and total areas were calculated using ImageJ Fiji.  
 
Table 7: Blocking Solution for IHC 
Component Final Concentration Source Reference 
 
PBS 
10% Triton X100 
Normal Horse Serum (NHS) 



















Table 8: Washing Solution for IHC  
 
 
Table 9: Primary Antibodies used for IHC 
Marker Host Dilution Source Reference 
p27 Mouse 1:100 BD Biosciences 610241 
     
TH Rabbit 1:300 Pel Freez P40101-150 
     
TH Sheep 1:300 Pel Freez P60101-150 
     
Nurr1 Rabbit 1:100 Santa Cruz SC-5568 
     
Pitx3 Rabbit 1:1000 Gift; M. Smidt (UVA, NL) N/A 
     
Ki67 Rabbit 1:100 Invitrogen MA5-14520 
     
Sox2 Rabbit 1:300 Millipore AB5603 
     
Ngn2 Goat 1:100 Santa Cruz SC-19233 
     
Foxa2 Goat 1:50 Santa Cruz SC-6554 
     
Lmx1a Rabbit 1:300 Millipore AB10533 
 
Component Final Concentration Source Reference 
 
PBS 












Table 9 Continued: Primary Antibodies used for IHC 
Marker Host Dilution Source Reference 
Casp3 Rabbit 1:500 Cell Signaling 9664 
     
BIII-Tub Mouse 1:1000 Biolegend 801202 
     
Gfap Mouse 1:300 BD Pharmagen 556327 
     




Table 10: Secondary Antibodies  
Antibody Host Dilution Source Reference 
Alexa Flour 555 (red) Donkey α-mouse 1:500 Life Technologies A31570 
     
Alexa Flour 555 (red) Donkey α-rabbit 1:500 Life Technologies A31572 
     
Alexa Flour 555 (red) Donkey α-goat 1:500 Life Technologies A21432 
     
Alexa Flour 488 (green) Donkey α-mouse 1:500 Life Technologies A21202 
     
Alexa Flour 488 (green) Donkey α-rabbit 1:500 Life Technologies A21206 
 
 
4.3 Immunocytochemistry (ICC) and image analysis 
Cells were fixed in 4% PFA for 10 minutes, washed 3 x 10 minutes with PBS 1X and 
left in blocking solution (Table 11) at room temperature for 30 minutes and incubated with 
primary antibody diluted in antibody solution (Table 12) overnight at 4˚C using the primary 
antibodies listed in Table 13. Primary antibodies were revealed with the corresponding 
secondary antibody (Table 10) diluted in antibody solution for 1 hour at room temperature. 
Nuclei were stained with Hoechst 33258 (0.2µg/mL, Invitrogen) diluted in PBS 1X for 10 
minutes. A fluorescence microscope (Leica DM IL LED) equipped with a digital camera (Leica 
DFC345FX) was used for image capture. For analysis, 6 separate fields were captured from at 




Table 11: Blocking solution for ICC 
Component Final Concentration Source Reference 
º 
PBS 
















Table 12: Antibody solution for ICC 
Component Final Concentration Source Reference 
 
PBS 

















Table 13: Antibodies used for ICC 
Marker Host Dilution Source Reference 
p27 Mouse 1:100 BD Biosciences 610241 
     
TH Rabbit 1:300 Pel Freez P40101-150 
     
TH Sheep 1:300 Pel Freez P60101-150 
     
Nurr1 Rabbit 1:100 Santa Cruz SC-5568 
     
Ki67 Rabbit 1:100 Invitrogen  MA5-14520 
     
Sox2 Rabbit 1:300 Millipore AB5603 
     
Casp3 Rabbit 1:500 Cell Signaling 9664 
     
BIII-Tub Mouse 1:1000 BioLegend 801202 
 
4.4 BrdU Treatment  
 For proliferation studies, we used the thymidine analog 5-bromo-2’-deoxyuridine 
(BrdU) that incorporates into newly synthesized DNA of actively dividing cells. For in vivo 
studies, we injected pregnant females with 50µg BrdU/g of body weight at days equivalent to 
E11.5 and sacrificed 24 hours later at E12.5. Tissue was then processed as described above 
(Section 1.3). For IHC studies, slides were prepared as described in Section 4.2. After de-
gelatinizing, slides were treated with 2M HCl for 30 minutes at 37ºC. Slides were washed 3 x 
10 minutes with PBS 1X to equilibrate the pH and IHC was completed as normal. HCl treatment 
was repeated if necessary. For double IHC studies, slides were treated with HCl after incubating 
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with the first primary antibody. For in vitro studies, BrdU was added to the medium of 
differentiating cells (Vf = 5µM BrdU) and left for 4 hours. After fixing the cells with 4% PFA 
(described above, Section 4.3), cells were treated with 2M HCl for 30 minutes at 37ºC and 
washed 3 x 10 minutes with PBS 1X to equilibrate the pH. ICC was performed as described in 
Section 4.3. HCl treatment was repeated if necessary. For double ICC studies, cells were treated 
with HCl after incubating with the first primary antibody. 
4.5 Western Blot 
For western blot (WB) analysis, 25μg of protein sample was boiled for 5 minutes and 
subjected to electrophoresis on a 10% SDS-PAGE gel using the Mini-PROTEAN Tetra Cell 
system, according to the manufacturer’s instruction. Gels were transferred to nitrocellulose 
membranes (GE Healthcare), blocked in 5% nonfat-milk with 0.05% Tween 20 (Sigma) in Tris 
buffered saline (TBS) for 1 hour at room temperature and incubated with primary antibody 
(Table 14) at 4˚C overnight. The blots were developed using peroxidase-conjugated horse anti-
mouse (HAMPO 1:2500, Atom) or peroxidase-conjugated goat anti-rabbit (GARPO 1:2000, 
Atom). Chemiluminescent HRP substrate (Millipore) was used to visualize the secondary 
antibody according to the manufacturer’s instruction.  
 
 
Table 14: Antibodies used for WB 
Marker Host Dilution Source Reference 
B-actin Mouse 1:1000 Sigma A5441 
     
p27 Mouse 1:1000 BD Biosciences 610241 
     
TH Rabbit 1:500 Pel-Freez P40101-150 
     
NeuroD1 Rabbit 1:1000 Millipore ABE991 
     
Sox2 Rabbit 1:100 Millipore AB5603 
     
Oct4 Rabbit 1:500 Santa Cruz SC-9081 
 
4.6 RNA extraction  
 For in vivo studies, VM tissue was dissected directly from the brain of E11.5, E12.5, 
E13.5 and E14.5 embryos with the aid of a magnifier under sterile conditions. As described 
above (Section 2.2), the midbrain of the developing rodent brain is a tube recognized by its 
characteristic curve behind the cortex, which was removed and placed in cold, sterile PBS 1X. 
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Straight surgical micro-scissors were then used to remove the upper curve of the midbrain, 
corresponding to the dorsal mesencephalon (DM). The bottom curve, corresponding to the VM 
was flattened and recognized by its “butterfly” shape, from which the edges were trimmed with 
a sterile razor blade, if necessary. Each dissected VM was maintained separately and bodies 
were saved for genotyping. Due to the smaller size of the midbrain at E11.5, after genotyping, 
at least 2 VMs of the same genotype were combined in order to provide enough tissue for RNA 
extraction.  
 For in vitro studies, cells in feeder-free conditions (such as cells in proliferation and 
EBs) were collected for RNA extraction directly from the well, first by washing 2-3 times with 
PBS 1X and then by adding RLT lysis buffer. Cells with feeders were left in a solution of 
Hank’s Buffered Saline Solution (HBSS) with HEPES for at least 30 minutes, and colonies 
were later lifted from the feeder layer with the aid of a syringe.  
Total RNA extraction was performed using RNeasy Mini Isolation Kit (Qiagen), 
following manufacturer’s instruction. RNA was quantified using the Nanodrop (Tecan) system, 
and the 260/280 ratio measure was used to ensure pure RNA samples. 
4.7 RT-qPCR analysis  
1µg of total RNA was reverse-transcribed in a two-step process, starting with a 12.8µL 
reaction mixture (containing 1µg RNA, 0.5µL 25mM dNTPs, 150ng random hexamer and H20) 
placed in a SimpliAmpTM Thermal Cycler (Applied Biosystems) set to 65ºC for 5 minutes. 
These tubes were then placed directly on ice for 2 minutes and 4µL 5x buffer, 2µL 0.1M DTT, 
0.2µL RNasin and 1µL SuperScriptIII-RT (Life Technologies) was added to each tube, 
reaching a final volume of 20µL, and again placed in the thermal cycler in a program consisting 
of 25ºC for 10 minutes, 50ºC for 60 minutes and finally 75ºC for 10 minutes before cooling to 
a holding temperature of 4ºC. cDNA was analyzed by RT-qPCR using the SYBR-green system 
(Applied Biosystems) according to the manufacturer’s instruction. 10ng total cDNA and 10µM 
of primers were used in a 15µL reaction mixture. Primers were specifically designed to span 
exon sequences for relative mRNA level quantification. All primers used are listed in Tables 
15-22. An initial trial was performed testing various housekeeping genes, with Gapdh providing 
the most consistent results. All experiments were therefore normalized to Gapdh expression 
levels. Relative RNA levels were estimated using the 2-ΔΔCt relative quantification method. 




Table 15: RT-qPCR primers-Housekeeping genes 





104 base pairs 





78 base pairs 





86 base pairs 





65 base pairs 





119 base pairs 
   
Rplp0 Forward 
Rplp0 Reverse 
5’- ACTGGTCTAGGACCCGAGAAG -3’ 
5’-CTCCCACCTTGTCTCCAGTC-3’ 
124 base pairs 
 
 
Table 16: RT-qPCR primers-DA neuron developmental markers 





84 base pairs 





106 base pairs 





64 base pairs 





104 base pairs 





71 base pairs 





60 base pairs 





65 base pairs 





76 base pairs 











Table 17: RT-qPCR primers-Pluripotency markers 





76 base pairs 





129 base pairs 





62 base pairs 





95 base pairs  
 
Table 18: RT-qPCR primers-NeuroD proteins 





90 base pairs 





64 base pairs 





61 base pairs 





85 base pairs 





61 base pairs 
 
Table 19: RT-qPCR primers-Cyclins and CDKs 
Marker Primer pair Amplicon length 




78 base pairs 
   
Cyclin D2 Forward 
Cyclin D2 Reverse 
5’-GCTGTGCATTTACACCGACA-3’ 
5’-TCAGCTTACCCAACACTACCAG-3’ 
77 base pairs 
   
Cyclin D3 Forward 
Cyclin D3 Reverse 
5’-GGCATACTGGATGCTGGAG-3’ 
5’-CCAGGTAGTTCATAGCCAGAGG-3’ 
77 base pairs 





76 base pairs 





86 base pairs 
   
Cyclin A Forward 
Cyclin A Reverse 
5’-GCTCTCTACACAGTCACAGGACA-3’ 
5’-AAGGTCCACAAGACAAGGCTTA-3’ 
96 base pairs 
   
Cyclin E  Forward 
Cyclin E Reverse 
5’-TTTCTGCAGCGTCATCCTC-3’ 
5’-TCTCTGTGGAGCTTATAGACTTCG-3’ 
86 base pairs 
   




89 base pairs 
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Table 19 Continued: RT-qPCR primers-Cyclins and CDKs 
Marker Primer Pair Amplicon Length 
Cyclin B Forward 
Cyclin B Reverse 
5’-GTGTGTGAACCAGAGGTGGA-3’ 
5’-GGCTTGGAGAGGGATTATCA-3’ 
72 base pairs 





99 base pairs 
 
Table 20: RT-qPCR primers-Germ layers 





99 base pairs 





72 base pairs 





70 base pairs 





61 base pairs 





73 base pairs 





73 base pairs 
 
Table 21: RT-qPCR primers-Alternative phenotypes 





73 base pairs 





67 base pairs 





88 base pairs 





110 base pairs 





71 base pairs 





87 base pairs 





90 base pairs 





88 base pairs 





76 base pairs 
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Table 22: RT-qPCR primers-Miscellaneous  





126 base pairs 





77 base pairs 





92 base pairs 





94 base pairs 





70 base pairs 





118 base pairs 
   
P21 Forward 
p21 Reverse 
5’- AACATCTCAGGGCCGAAA -3' 
5’- TGCGCTTGGAGTGATAGAAA -3' 
62 base pairs 
 
 
5. STATISTICAL ANALYSIS  
Statistical tests were run using GraphPad Prism 6.0. Results are shown as the average ± 
S.E.M. of data from 3-8 animals (n=3-8) or from 3 separate in vitro experiments (n=3). Mean 
values between two groups were compared using a two-tailed Student’s t-test for independent 
samples. Mean values between more than two groups were compared using a one-way analysis 
of variance (ANOVA) followed by Tukey’s post-hoc test. P-values <0.05 were considered 































EXPRESSION PATTERN OF P27 IN THE DEVELOPING MOUSE BRAIN 
The main purpose of this thesis is studying the effects of the protein p27 on the development of 
DA neurons. Since functions of p27 have yet to be described in the midbrain, we first 
established an expression pattern of p27 in the developing VM from E11.5 to E14.5, which is 
when DA neurogenesis is known to take place (Arenas et al 2015).  
1.1 Dissecting the VM 
In order to establish an expression pattern for p27 in the developing midbrain, we first dissected 
the VM directly from the brain for RNA or protein extraction, as indicated by the line through 
the recognizable curve present during embryonic mouse brain development (Figure 1.1 A). We 
then obtained coronal sections of embryo brains for IHC studies in order to establish expression 
patterns of factors known to be present in different developmental areas that arise during DA 
neuron development (Figure 1.1 A’-A”), and specifically studied the co-expression of these 
factors with p27.  
1.2 p27 Expression pattern in the VM 
First, we studied the expression of p27 and TH, using TH as a positive control of VM tissue 
(Figure 1.2). We saw a steady increase in the mRNA expression of both markers from E11.5 to 
E14.5 (Figure 1.2 A,B), indicating that we had correctly dissected tissue of the VM, that p27 is 
present in the developing midbrain and that its expression increases as development progresses. 
These results were confirmed by WB studies (Figure 1.2 C). 
Next, we sectioned brains for IHC studies to see the expression pattern of p27 in the 
developing VM. At E11.5, we saw a clear pattern for p27, whose expression was restricted to 
the IZ and MZ, and completely absent from the VZ (Figure 1.2 D). As development progressed, 
the percentage of p27 expression increased in relation to Hoechst expression (Figure 1.2 F),  





Figure 1.2: p27 expression pattern in the VM. A) p27 mRNA levels in the developing VM. B) TH 
mRNA levels in the developing VM. C) TH and p27 protein expression in the developing VM. D) 
IHC of p27 expression pattern in the developing VM; scale bars = 100µm. E) p27 and TH co-
expression in the developing VM; scale = bars 100µm (top panels) and 50µm (bottom panels). 
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which was accompanied by a progressive decrease in the area of the VZ. The expression of TH 
was shown to increase as development progressed, with only 56.0 ± 5.6 total TH+ cells per 
section at E11.5 which increased to 637.2 ± 17.3 total TH+ cells per section at E14.5 (Figure 
1.2 E,G). These results are expected, and also serve as a positive control of midbrain tissue. 
When studying the co-expression of p27 with TH, we saw that all TH+ cells were p27+TH+ 
double positive from E11.5 to E14.5 (Figure 1.2 H). 
These results allow us to conclude that p27 is expressed in the developing VM and 
increases as development progresses. Furthermore, the expression pattern of p27 is restricted 
to the IZ and MZ, and completely absent from the VZ.  
1.3 p27 co-expression with DA neuron markers  
Next, we studied the co-expression of p27 with the early DA neuron marker Nurr1 and the 
mature DA neuron marker Pitx3. The expression of Nurr1 increased as development 
progressed, from 152.0 ± 29.6 total Nurr1+ cells per section at E11.5 to 669.6 ± 54.4 total 
Nurr1+ cells per section at E14.5 (Figure 1.3 A,C). In almost all cases, Nurr1+ cells were 
p27+Nurr1+ double positive (Figure 1.3 D).  
Lastly, we studied the co-expression of p27 with the late DA neuron marker Pitx3. At 
E11.5 there was very little Pitx3 expression, with 38.4 ± 6.4 total Pitx3+ cells per section at 
E11.5, which increased to 492.2 ± 5.3 total cells per section at E14.5 (Figure 1.3 B,E). As in 
the case with TH, all Pitx3+ cells were p27+Pitx3+ double positive (Figure 1.3 F).  
These results allow us to conclude that we have successfully located VM sections based 
on appropriate TH, Nurr1 and Pitx3 expression, and that p27 is co-expressed with all three, 
indicating a possible function of p27 in the development of these markers and thereby DA 
neurons. 
1.4 p27 co-expression with DA neuron developmental markers 
Knowing that p27 was co-expressed with markers of mature DA neurons, we next studied the 
co-expression of p27 with two markers important during their early development: Foxa2 which 
is necessary for proper regionalization and patterning of the FP (Ang and Rossant 1994, Ang 
2009) and Lmx1a which is necessary for the proper specification of DA neurons (Andersson et 
al 2006b).  
We saw that Foxa2 expression appeared to reach a consistent level, with approximately 
90% of cells in the VM expressing Foxa2 (Figure 1.4 A,C). Foxa2 is expressed in all three 




number of p27+Foxa2+ double positive cells (from 42.6% ± 15.5 at E11.5 to 94.8% ± 1.8 at 
E14.5, Figure 1.4 D), consistent with an increased number of proliferating precursors exiting 
the cell cycle at later developmental stages.    
When studying Lmx1a expression, we saw a peak of total Lmx1a+ cells at E12.5-E13.5 
(378.1 ± 10.9 total Lmx1a+ cells at E12.5 and 350.6 ± 19.3 total Lmx1a+ cells at E13.5, Figure 
1.4 B,E). Similar to Foxa2, we saw that Lmx1a expression spanned the three developmental 
zones and the number of p27+Lmx1a+ double positive cells increased from E11.5 to E14.5, 
again consistent with an increased number of proliferating precursors exiting the cell cycle at 
later developmental stages (Figure 1.4 F). 
 
Figure 1.3: p27 co-expression with DA neuron markers. Co-expression and quantification of DA 
neuron markers with p27 from E11.5 to E14.5: A) IHC of Nurr1 and p27 co-expression. B) IHC of 
Pitx3 and p27 co-expression. C) Quantification of total Nurr1+ cells. D) Quantification of 
p27+Nurr1+ double positive cells. E) Quantification of total Pitx3+ cells. F) Quantification of 










Figure 1.4: p27 co-expression with DA neuron developmental markers. Co-expression and 
quantification of DA neuron developmental markers with p27 from E11.5 to E14.5: A) IHC of Foxa2 
and p27 co-expression. B) IHC of Lmx1a and p27 co-expression. C) Quantification of Foxa2+ cells in 
relation to Hoescht. D) Quantification of p27+Foxa2+ double positive cells. E) Quantification of total 
Lmx1a+ cells. F) Quantification of p27+Lmx1a+ double positive cells. Scale bars = 100µm. 
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1.5 p27 co-expression with DA precursor markers 
In the context of the VM, we know that Ngn2+ cells are DA neuron specific precursors (Kele 
et al 2006). Ngn2 expression was high at early stages of development (101.4 ± 19.8 Ngn2+ cells 
at E11.5) and steadily decreased until it was completely absent by E14.5 (Figure 1.5 A,B). Ngn2 
expression was mainly restricted to the VZ, with some Ngn2+ cells also present in the IZ. The 
IZ can be distinguished in these sections, as it is composed of the small region where we see 
both Ngn2+ and p27+ cells, although there was very little co-expression of these markers 
(Figure 1.5 C). 
Figure 1.5: p27 co-expression with DA precursor markers. Co-expression and quantification of 
DA neuron precursor markers with p27 from E11.5 to E14.5: A) IHC of Ngn2 and p27 co-expression. 
B) Quantification of total Ngn2+ cells. C) Quantification of p27+Ngn2+ double positive cells. Scale 
bars = 50µm. 
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1.6 p27 co-expression with mitotic cell markers in the VM 
Knowing the importance of proper cell cycle exit in promoting the correct transition from 
proliferating precursors to differentiating neurons, we next studied the expression of the cell 
cycle marker Ki67 and the general neural precursor Sox2.  
 Ki67 expression was exclusively restricted to the VZ, with expression decreasing from 
42.9% ± 9.1 at E11.5 to 3.0% ± 1.7 at E14.5 (Figure 1.6 A,C). This expression was entirely 
complementary to p27, with no p27+Ki67+ double positive cells present during the 
development of the VM (Figure 1.6 D).  
Sox2+ expression was similar to Ki67 expression, where we see an expression pattern 
exclusively restricted to the VZ. Sox2 expression decreased from 47.0% ± 4.3 at E11.5 to 2.9% 
Figure 1.6: p27 co-expression with mitotic cell markers in the VM. Co-expression and 
quantification of mitotic cell markers and p27 from E11.5 to E14.5: A) IHC of Ki67 and p27 co-
expression. B) IHC of Sox2 and p27 co-expression. C) Quantification of Ki67+ cells in relation to 
Hoescht. D) Quantification of p27+Ki67+ double positive cells. E)  Quantification of Sox2+ cells in 
relation to Hoescht. F) Quantification of p27+Sox2+ double positive cells. Scale bars = 50µm. 
 
72 
± 0.6 at E14.5 (Figure 1.6 B,E). Again, we saw no p27+Sox2+ double positive cells during the 
development of the VM (Figure 1.6 F)  
 
In summary, we have established an expression pattern for p27 in the developing VM, where 
p27 is restricted to the IZ and MZ, and its expression increases as development progresses. p27 
is co-expressed with DA neuron markers throughout development, its co-expression increases 
with the developmental markers Foxa2 and Lmx1a as development progresses, and p27 
expression is entirely complementary to the cell cycle marker Ki67 and the neural precursor 
marker Sox2. p27 was not shown to be co-expressed with the DA precursor marker Ngn2, 























EFFECTS OF P27 DEFICIENCY ON THE DEVELOPING MOUSE BRAIN 
After establishing an expression pattern for p27 in the VM, and an expression pattern for the 
co-expression of key markers important during DA neuron development, we studied the effects 
of p27 deficiency on the developing mouse midbrain by comparing the embryonic brain of  p27 
deficient (p27-/-) mice to wild type (p27+/+) controls, from E11.5 to E14.5.  
2.1 p27 deficiency decreases early DA neuron development 
We first wanted to examine the effects of p27 deficiency on TH development in the midbrain. 
At E11.5, we saw a significant decrease in TH expression in brain sections (28.0 ± 3.0 TH+ 
cells in p27-/- mice compared to 56.6 ± 5.6 TH+ cells in controls; p<0.001***) as well as 
decreased mRNA levels (0.77 ± 0.16 relative TH mRNA levels in p27-/- mice compared to 1.02 
± 0.25 in controls; p<0.05*) (Figure 2.1 A-A”).  These results were maintained at E12.5, where 
we again saw a significant decrease in TH expression in brain sections (73.6 ± 6.7 TH+ cells in 
p27-/- mice compared to 116 ± 6.3 TH+ cells in controls; p<0.01**) and decreased mRNA 
levels (0.71 ± 0.18 relative TH mRNA levels in p27-/- mice compared to 1.02 ± 0.24 in controls; 
Figure 2.1: p27 deficiency decreases early DA neuron development. A-A’) Coronal sections of 
E11.5 VM showing decreased TH expression in p27 deficient mice as compared to control and A”) 
decreased TH mRNA levels. B-B’) Coronal sections of E12.5 VM showing decreased TH expression 
in p27 deficient mice as compared to control and B”) decreased TH mRNA levels. Data represents 
mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis was performed using Student’s t-test 
between control and p27 deficient mice; p<0.05*; p<0.01**; p<0.001***. Scale bars = 50µm. 
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p<0.05*) (Figure 2.1 B-B”). These results allow us to conclude that p27 deficiency  
significantly decreases DA neuron production at early stages of development.  
2.2 p27 deficiency decreases expression of DA neuron markers 
We further examined the effects of p27 deficiency on DA neuron development by studying the 
effects of p27 deficiency on the DA neuron markers Nurr1 and Pitx3. We saw a significant 
decrease in Nurr1 (68.6 ± 16.7 Nurr1+ cells in p27-/- mice compared to 152.0 ± 29.6 Nurr1+ 
cells in controls; p<0.01**; Figure 2.2 A-A’) and Pitx3 (2.3 ± 3.9 Pitx3+ cells in p27-/- mice 
compared to 38.4 ± 6.4 Pitx3+ cells in controls; p<0.0001****; Figure 2.2 C-C’) at E11.5, 
which was confirmed by RT-qPCR studies (0.54 ± 0.37 relative Nurr1 mRNA levels in p27-/- 
mice compared to 1.01 ± 0.13; p<0.001**; Figure 2.2 A” and 0.49 ± 0.14 relative Pitx3 mRNA 
levels in p27-/- mice compared to 1.02 ± 0.39 in controls; p<0.01**; Figure 2.2 C”).  
 Similar results were obtained at E12.5, where p27 deficiency, again caused a significant 
decrease in the expression of both Nurr1 (165.3 ± 43.6 Nurr1+ cells in p27-/- mice compared 
to 274.8 ± 13.1 in controls; p<0.05*; Figure 2.2 B-B’) and Pitx3 (105.2 ± 3.2 Pitx3+ cells in 
p27-/- mice compared to 191.1 ± 14.1 in controls; p<0.001**; Figure 2.2 D-D’). These results 
were confirmed by RT-qPCR studies (0.83 ± 0.14 relative Nurr1 mRNA levels in p27-/- mice 
compared to 1.04 ± 0.07 in controls: p<0.01**; Figure 2.2 B” and 0.62 ± 0.19 relative Pitx3 
mRNA levels in p27-/- mice compared to 1.05 ± 0.19 in controls; p<0.001**; Figure 2.2 D”)  
 These results further confirm that p27 deficiency significantly decreases the production 
of DA neurons during early developmental stages. 
2.3 p27 deficiency does not affect early regionalization or specification  
Since we saw that p27 co-expression with the regionalization marker Foxa2 and the 
specification marker Lmx1a increased as development progressed, we wanted to see the effects 
p27 deficiency had on the early expression of these markers. We saw no significant differences 
in the expression of Foxa2 in p27 deficient mice compared to controls in brain sections (90.6% 
± 1.4 Foxa2 expression in p27-/- mice compared to 90.3% ± 4.7 in controls) or at the mRNA 
level (0.93 ± 0.26 relative Foxa2 mRNA levels in p27-/- mice compared to 1.04 ± 0.29 in 
controls) (Figure 2.3 A-A”). Similarly, we saw no significant differences in the expression of 
Lmx1a in p27 deficient mice compared to controls, as IHC studies showed 264.3 ± 15.1 
Lmx1a+ cells in p27 deficient mice compared to 272.7 ± 4.7 Lmx1a+ cells in controls (Figure 




Figure 2.2: p27 deficiency decreases expression of DA neuron markers. A-A’) Coronal sections 
of E11.5 VM showing decreased Nurr1 expression in p27 deficient mice as compared to control and 
A”) decreased Nurr1 mRNA levels. B-B’) Coronal sections of E12.5 VM showing decreased Nurr1 
expression in p27 deficient mice as compared to control and B”) decreased Nurr1 mRNA levels. C-
C’) Coronal sections of E11.5 VM showing decreased Pitx3 expression in p27 deficient mice as 
compared to control and C”) decreased Pitx3 mRNA levels. D-D’) Coronal sections of E12.5 VM 
showing decreased Pitx3 expression in p27 deficient mice as compared to control and D”) decreased 
Pitx3 mRNA levels.  Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis 
was performed using Student’s t-test between control and p27 deficient mice; p<0.05*; p<0.01**; 
p<0.0001****. Scale bars = 50µm. 
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Figure 2.3: p27 deficiency does not affect early regionalization or specification markers. A-A’) 
Coronal sections of E11.5 VM showing unaltered Foxa2 expression and A”) unaltered Foxa2 mRNA 
levels in p27 deficient mice compared to controls. B-B’) Coronal sections of E12.5 VM showing 
unaltered Foxa2 expression and B”) unaltered Foxa2 mRNA levels in p27 deficient mice compared to 
controls. C-C’) Coronal sections of E11.5 VM showing unaltered Lmx1a expression and C”) unaltered 
Lmx1a mRNA levels in p27 deficient mice compared to controls. D-D’) Coronal sections of E12.5 VM 
showing unaltered Lmx1a expression and D”) unaltered Lmx1a mRNA levels in p27 deficient mice 
compared to controls. Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis 
was performed using Student’s t-test between control and p27 deficient mice. Scale bars = 50µm. 
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in p27-/- mice compared to 1.08 ± 0.27 in controls; Figure 2.3 C”). 
 These results were maintained at E12.5, with no significant differences in Foxa2 
expression in brain sections (90.2% ± 1.4 Foxa2 expression in p27-/- mice compared to 92.9% 
± 1.4 in controls) or at the mRNA level (1.22 ± 0.17 relative Foxa2 mRNA levels in p27-/- 
mice compared to 1.04 ± 0.32 in controls) (Figure 2.3 B-B”). Again, we did not observe 
significant differences in Lmx1a expression in brain sections (189.9 ± 13.8 Lmx1a+ cells in 
p27-/- mice compared to 189.1 ± 21 in controls) or at the mRNA level (1.04 ± 0.23 relative 
Lmx1a mRNA levels in p27-/- mice compared to 1.05 ± 0.38 in controls) (Figure 2.3 D-D”). 
 These results allow us to conclude that p27 deficiency does not decrease DA neuron 
development by affecting early regionalization (Foxa2) or specification (Lmx1a) in the 
developing midbrain.  
2.4 p27 deficiency increases mitotic precursors in the VM 
Since we saw no effect on early developmental markers, we next investigated the effects of p27 
deficiency on the cell cycle marker Ki67 and the neural precursor marker Sox2. At E11.5, there 
was a significant increase in the expression of Ki67 in the VM of p27 deficient mice (70.5% ± 
3.5 Ki67 expression in p27-/- mice compared to 42.9% ± 9.8 in controls; p<0.001***), which 
was confirmed by RT-qPCR studies (1.22 ± 0.16 relative Ki67 mRNA levels in p27-/- mice 
compared to 1.02 ± 0.12 in controls; p< 0.01**) (Figure 2.4 A-A”). Similar results were 
obtained for Sox2 expression (73.1% ± 1.0 Sox2 expression in p27-/- mice compared to 40.6% 
± 9.5 in controls; p<0.001***), which was also confirmed by RT-qPCR studies (2.27 ± 1.13 
relative Sox2 mRNA levels in p27-/- mice compared to 1.13 ± 0.49 in controls; p<0.05*) 
(Figure 2.4 C-C”).  
 The results observed at E11.5 were maintained at E12.5, where we saw a significant 
increase in both Ki67 expression (35.7% ± 6.8 Ki67 expression in p27-/- mice compared to 
14.8% ± 3.8 in controls; p<0.01*; Figure 2.4 B-B”) and Sox2 expression (40% ± 7.8 Sox2 
expression in p27-/- mice compared to 20.5% ± 5.5 in controls; p<0.05*; Figure 2.4 D-D’). 
These results were further conformed by RT-qPCR studies (1.41 ± 0.2 relative Ki67 mRNA 
levels in p27-/- mice compared to 1.02 ± 0.23 in controls; p<0.05*; Figure 2.4 C” and 1.51 ± 
0.24 relative Sox2 mRNA levels in p27-/- mice compared to 1.03 ± 0.28 in controls; p<0.05*; 
Figure 2.4 D”). This allows us to conclude that p27 deficiency significantly increases the 





Figure 2.4: p27 deficiency increases mitotic precursors in the VM. A-A’) Coronal sections of 
E11.5 VM showing increased Ki67 expression in p27 deficient mice as compared to control and A”) 
increased Ki67 mRNA levels. B-B’) Coronal sections of E12.5 VM showing increased Ki67 
expression in p27 deficient mice as compared to control and B”) increased Ki67 mRNA levels. C-C’) 
Coronal sections of E11.5 VM showing increased Sox2 expression in p27 deficient mice as compared 
to control and C”) increased Sox2 mRNA levels. D-D’) Coronal sections of E12.5 VM showing 
increased Sox2 expression in p27 deficient mice as compared to control and D”) increased Sox2 
mRNA levels.  Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis was 
performed using Student’s t-test between control and p27 deficient mice; p<0.05*; p<0.01**; 
p<0.001***. Scale bars = 50µm. 
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2.5 p27 deficiency increases cell proliferation 
After seeing an increase in the cell cycle marker Ki67, we wanted to check the effect of p27 
deficiency on proliferation. We injected pregnant females at E11.5 with BrdU and extracted the 
embryos 24 hours later. We saw a significant increase in BrdU expression in p27 deficient mice 
as compared to controls (32.5% ± 4.4 BrdU+ cells in p27-/- mice compared to 20.8% ± 5.5 
BrdU+ cells in controls; p<0.05*; Figure 2.5 A,B). These results were confirmed by looking at 
the marker PCNA at E12.5 (Figure 2.5 C,D). Therefore, p27 deficiency increases cell 







Figure 2.5: p27 deficiency increases proliferation in the VM. A,B) Coronal sections of E12.5 VM 
showing increased BrdU expression in p27 deficient mice as compared to control. C,D) Coronal 
sections of E12.5 VM showing increased PCNA expression in p27 deficient mice as compared to 
control. Data represents mean ± S.E.M. (n=3 for each experiment). Statistical analysis was performed 
using Student’s t-test between control and p27 deficient mice; p<0.05*. Scale bars = 50µm. 
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2.6 p27 deficiency increases pool of proliferating precursors 
We next double stained sections from BrdU-treated mice with either Ki67 or Sox2 and 
quantified the co-expression of these markers. Since we saw increased expression of Ki67 and 
BrdU separately, we can expect to see an increase in the co-expression of these markers. We 
saw that the number of total BrdU+Ki67+ double positive cells increased significantly in p27 
deficient mice (120.0 ± 1.4 BrdU+Ki67+ double positive cells) compared to controls (58.0 ± 
2.8 BrdU+Ki67+ double positive cells; p<0.0001****; Figure 2.6 A-A’), consistent with our 
previous results. When calculating Ki67+BrdU+ double positive cells in relation to total Ki67+ 
cells, we did not see any differences between p27 deficient mice and controls (97.4% ± 1.5 
BrdU+Ki67+/Total Ki67+ cells in p27-/- mice compared to 96.1% ± 0.9 BrdU+Ki67+/Total 
Ki67+ cells in controls; Figure 2.6 A,A”). 
Similar results were obtained for total BrdU+Sox2+ cells (183.5 ± 30.4 total 
BrdU+Sox2+ cells in p27-/- mice compared to 100.5 ± 3.5 in controls; p<0.05*; Figure 2.6 C-
C’). Again, upon calculating BrdU+Sox2+ cells in relation to Sox2+ cells, we see no differences 
between p27 deficeint mice and controls (95.4% ± 2.9 BrdU+Sox2+/Total Sox2+ cells in      
p27-/- mice compared to 97.3% ± 0.7 in controls; Figure 2.6 C,C”).  
To confirm these results, we studied another marker of proliferation: PCNA. Again, we 
saw significant differences between p27 deficient mice and controls when comparing total 
PCNA+Ki67+ double positive cells (110.0 ± 1.4 PCNA+Ki67+ double positive cells in p27-/- 
mice compared to 73.5 ± 20.5 in controls; p<0.05*; Figure 2.6 B-B’), but not when comparing 
PCNA+Ki67+/Total Ki67 cells (97.4% ± 1.1 PCNA+Ki67+/Total Ki67 in p27-/- mice 
compared to 96.3% ± 2.8 in controls; Figure 2.6 B,B”). Similar results were obtained for total 
PCNA+Sox2+ double positive cells (148.5  ± 14.8 total PCNA+Sox2+ double positive cells in 
p27-/- mice compared to 92.5 ± 17.7 in controls; Figure 2.6 D-D’) and PCNA+Sox2+/Total 
Sox2+ (97.5% ± 1.4 double positive cells in p27-/- mice compared to 97% ± 0.1 in controls; 
Figure 2.6 D,D”). Though the increase observed for total PCNA+Sox2+ double positive cells 
was not significant, this is most likely due to lack of sufficient biological replicates. However, 
in all cases, the total double-positive expression is near 100%, meaning that Ki67 and Sox2 can 
be considered indirect measures of proliferation, and that p27 deficiency increases the number 
of proliferating precursors in the developing VM. 
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Figure 2.6: p27 deficiency increases pool of proliferating precursors. A-A”) Coronal sections of 
E12.5 VM showing BrdU and Ki67 co-expression and how all Ki67+ cells are also BrdU+. B-B”) 
Coronal sections of E12.5 VM showing PCNA and Ki67 co-expression and how all Ki67+ cells are 
also PCNA+. C-C”) Coronal sections of E12.5 VM showing BrdU and Sox2 co-expression and how 
all Sox2+ cells are also BrdU+. D-D”) Coronal sections of E12.5 VM showing PCNA and Sox2 co-
expression and how all Sox2+ cells are also PCNA+.  Data represents mean ± S.E.M. (n=3 for each 
experiment). Statistical analysis was performed using Student’s t-test between control and p27 
deficient mice; p<0.05*; p<0.0001****. Scale bars = 50µm. 
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2.7 p27 deficiency increases DA neuron precursors 
We have seen that p27 deficiency significantly decreases DA neurons at early developmental 
stages, yet, we have also seen a significant increase in proliferating neural precursors. In order 
to study this effect in more detail, we analyzed the expression of Ngn2, a DA neuron precursors-
specific marker in the context of the VM. We initially believed that p27 could have an effect 
on increasing the general pool of neural progenitors but decreasing the number of DA neuron-
specific precursors. Contrary to what we expected, we saw a significant increase in Ngn2+ 
expression in p27 deficient mice at E11.5 as compared to controls (150.4 ± 15 Ngn2+ cells in 
p27-/- mice compared to 101.3  ± 16.2 in controls; p<0.01**; Figure 2.7 A-A’). These results 
were confirmed by RT-qPCR studies (1.29 ± 0.12 relative Ngn2 mRNA levels in p27-/- mice 
compared to 1.02 ± 0.27 in controls; p<0.05*; Figure 2.7 A”), and were maintained at E12.5 
(196.7 ± 10.4 Ngn2+ cells in p27-/- brains compared to 75 ± 8.8 in controls; p<0.001***; Figure 
2.7 B-B’ and 1.49 ± 0.4 relative Ngn2 mRNA levels in p27-/- mice compared to 1 ± 0.29 in 
controls; p<0.05*; Figure 2.7 B”). 
 
Figure 2.7: p27 deficiency increases DA neuron precursors. A-A’) Coronal sections of E11.5 VM 
showing increased Ngn2 expression in p27 deficient mice as compared to control and A”) increased 
Ngn2 mRNA levels. B-B’) Coronal sections of E12.5 VM showing increased Ngn2 expression in p27 
deficient mice as compared to control and B”) increased Ngn2 mRNA levels. Data represents mean ± 
S.E.M. (n=4-8 for each experiment). Statistical analysis was performed using Student’s t-test between 
control and p27 deficient mice; p<0.05*; p<0.01**; p<0.001***. Scale bars = 50µm. 
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2.8 p27 deficiency alters the distribution of DA neuron precursors 
After seeing an increase in DA neuron precursors, we did a more in-depth study of their 
distribution in the midbrain. We studied the expression of Ngn2+Sox2+ double positive cells, 
which represents the population of precursors destined to become DA neurons. At E11.5, we 
saw a significant increase in Ngn2+Sox2+ double positive cells in p27 deficient mice (170 ± 
19.5 Ngn2+Sox2+ cells) compared to controls (88 ± 14 Ngn2+Sox2+ cells; p<0.01**; Figure 
2.8 A,B). These results were confirmed at E12.5 (86.7 ± 7 Ngn2+Sox2+ cells in p27-/- mice 
compared to 30.3 ± 1.5 in controls; p<0.001***; Figure 2.8 C,D).  
This result is expected, as we saw an increase in both of these markers individually. We 
therefore decided to study the number of Ngn2+Sox2+ double positive cells with respect to the 
total number of Sox2+ cells, which would tell us the number of DA neuron precursors in 
relation to total neural progenitors. Again, we saw a significant increase in the number of 
Ngn2+Sox2+ double positive cells in relation to total Sox2+ cells in p27 deficient mice at E11.5 
(37.7 ± 4.8 Ngn2+Sox2+/Total Sox2+ cells) compared to controls (25.2 ± 1.3 
Ngn2+Sox2+/Total Sox2+ cells; p<0.05*; Figure 2.8 B’).  
These results were also confirmed at E12.5 (29.4 ± 2.3 Ngn2+Sox2+/Total Sox2+ cells 
in p27-/- mice compared to 21.5 ± 3.7 in controls; p<0.05*; Figure 2.8 D’). These results 
confirm that p27 deficiency increases the number of DA neuron precursors in the developing 
midbrain. We therefore studied the distribution of these cells, and saw that in control mice, 
Ngn2+Sox2+ double positive cells were centered around the border between the VZ and IZ, 
whereas in p27 deficient brains, these precursors were mainly interspersed in the VZ.  
Seeing this expression pattern, we studied the expression of Ngn2+Sox2- cells, which 
are DA neuron precursors that have exited the cell cycle, and reside mainly in the IZ. At E11.5, 
we saw no differences in Ngn2+Sox2- cells in p27 deficient mice (39.7 ± 9.1 Ngn2+Sox2- 
cells) compared to controls (39.7 ± 6.5 Ngn2+Sox2- cells; Figure 2.8 B”) and these results were 
maintained at E12.5 (25.3 ± 6.0 Ngn2+Sox2- cells in p27-/- mice compared to 23.0 ± 4.1 in 
controls; Figure 2.8 D”). These results allow us to conclude that p27 deficiency increases the 
number of DA neuron precursors, and alters their distribution in the VZ, without affecting their 




Figure 2.8: p27 deficiency alters the distribution of DA neuron precursors. A) Coronal sections 
of E11.5 VM showing co-expression of Ngn2 and Sox2. B-B”) Quantification of Ngn2+Sox2+ double 
positive cells of the VZ and Ngn2+Sox2- cells of the IZ at E11.5. C) Coronal sections of E12.5 VM 
showing co-expression of Ngn2 and Sox2. D-D”) Quantification of Ngn2+Sox2+ double positive cells 
of the VZ and Ngn2+Sox2- cells of the IZ at E12.5. Data represents mean ± S.E.M. (n=3 for each 
experiment). Statistical analysis was performed using Student’s t-test between control and p27 
deficient mice; p<0.05*; p<0.01**; p<0.001***. Scale bars = 50µm. 
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2.9 Effects of p27 deficiency are maintained at later stages of development 
Seeing an increased number of precursors suggests that these cells later differentiate, thereby 
giving rise to an increased number of DA neurons in the midbrain. To check this, we looked at 
the expression of the mature DA neuron markers TH and Pitx3 at later developmental stages. 
At E13.5, we saw that both TH expression (173.6 ± 40.6 TH+ cells in p27-/- mice compared to 
244.7 ± 13.0 TH+ cells in controls p<0.05*; Figure 2.9 A-A’) and Pitx3 expression (199.7 ± 
7.3 Pitx3+ cells in p27-/- mice compared to 238.2 ± 20.0 in controls; p<0.05*; Figure 2.8 C-
C’) remained decreased, and these results were confirmed by RT-qPCR experiments (0.75 ± 
1.70 relative TH mRNA levels in p27-/- mice compared to 1.01 ± 0.11 in controls; p<0.05; 
Figure 2.9 A” and 0.53 ± 0.14 relative Pitx3 mRNA levels in p27-/- mice compared to 1.02 ± 
0.20 in controls; p<0.001***; Figure 2.9 C”). Similar results were obtained at E14.5, both in 
brain sections (261.1 ± 17.0 TH+ cells in p27-/- mice compared to 318.7 ± 17.3 in controls; 
p<0.05*; Figure 2.9 B-B’ and 215.1 ± 14.2 Pitx3+ cells in p27-/- mice compared to 246.1 ± 5.3 
in controls; p<0.05*; Figure 2.9 D-D’) and in RT-qPCR studies (0.70 ± 0.10 relative TH mRNA 
levels in p27-/- mice compared to 1.23 ± 0.44 in controls; p<0.05*; Figure 2.9 B” and 0.63 ± 
0.20 relative Pitx3 mRNA levels in p27-/- mice compared to 1.14 ± 0.39 in controls; p<0.05*; 
Figure 2.9 D"). These results confirm that the effect p27 deficiency has on increasing 
proliferating precursors at early developmental stages does not increase DA neuron 
differentiation at later stages. 
2.10 Effects of p27 deficiency begin to recover at later stages of development 
Although the effects of p27 deficiency were maintained for mature DA neuron markers, we saw 
that by E13.5, the expression of Nurr1 was recovered in p27 deficient mice as compared to 
control, in both brain sections (252.0 ± 28.6 Nurr1+ cells in p27-/- mice compared to 289.8 ± 
55.7 in controls) and RT-qPCR experiments (0.95 ± 0.23 relative Nurr1 mRNA levels in       
p27-/- mice compared to 1.03 ± 0.28 in controls) (Figure 2.10 A-A”). These results were further 
confirmed at E14.5 (314.3 ± 59.7 Nurr1+ cells in p27-/- mice compared to 334.8 ± 54.4 in 
controls and 1.04 ± 0.15 relative Nurr1 mRNA levels in p27-/- mice compared to 1.05 ± 0.33 




Figure 2.9: Effects of p27 deficiency are maintained at later developmental stages. A-A’) Coronal 
sections of E13.5 VM showing decreased TH expression in p27 deficient mice as compared to control 
and A”) decreased TH mRNA levels. B-B’) Coronal sections of E14.5 VM showing decreased TH 
expression in p27 deficient mice as compared to control and B”) decreased TH mRNA levels. C-C’) 
Coronal sections of E13.5 VM showing decreased Pitx3 expression in p27 deficient mice as compared 
to control and C”) decreased Pitx3 mRNA levels. D-D’) Coronal sections of E14.5 VM showing 
decreased Pitx3 expression in p27 deficient mice as compared to control and D”) decreased Pitx3 
mRNA levels.  Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis was 
performed using Student’s t-test between control and p27 deficient mice; p<0.05*; p<0.001***. Scale 
bars = 100µm. 
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2.11 p27 deficiency alters the progression of DA neuron development 
Although we saw recovered Nurr1 levels by E13.5, we looked at the proper progression of DA 
neuron development by first investigating the number of Nurr1+ cells that had not yet acquired 
TH (Nurr1+TH- cells), which are DA-committed precursors residing in the IZ. We see an 
overall increase in total Nurr1+TH- precursors in p27 deficient mice (77.9 ± 15.4 Nurr1+TH-
cells in p27-/- mice compared to 42.0 ± 12.0 Nurr1+TH- cells in controls; p<0.01**; Figure 
2.11 A,A’) and in the overall percentage of Nurr1+TH- cells in relation to total Nurr1+ cells 
(31.3% ± 7.7 Nurr1+TH-/Nurr1+ cells in p27-/- mice compared to 16.2% ± 4.3 in controls; 
p<0.05*; **; Figure 2.11 A,A”). Therefore, although Nurr1 expression begins to recover by 
E13.5, the majority of these Nurr1+ cells remain as precursors in the IZ. This is further 
supported by studying the overall number of mature DA neurons as measured by Pitx3+TH+ 
cells. In this case, we saw a significant decrease in the overall number of Pitx3+TH+ double 
cells in p27 deficient mice (154.0 ± 23.5 Pitx3+TH+ cells) as compared to controls (260.8 ± 
4.7 Pitx3+TH+ cells; p<0.01**; Figure 2.11 B,B’) and a significant decrease in the percentage 
of TH+ cells that were also Pitx3+ (69.9% ± 12.7 Pitx3+TH+/Total TH+ cells in p27-/- mice 
compared to 92.3% ± 4.7 in controls; p<0.01**; Figure 2.11 B,B”). These results support that 
Figure 2.10: Effects of p27 deficiency begin to recover by later stages of development. A-A’) 
Coronal sections of E13.5 VM showing recovered Nurr1 expression in p27 deficient mice as compared 
to control and A”) recovered Nurr1 mRNA levels. B-B’) Coronal sections of E14.5 VM showing 
recovered Nurr1 expression in p27 deficient mice as compared to control and B”) recovered Nurr1 
mRNA levels. Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis was 
performed using Student’s t-test between control and p27 deficient mice. Scale bars = 100µm. 
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p27 deficiency alters the progression of DA neuron development and may cause a 
developmental delay. Whether these neurons fully recover and develop into properly 
functioning DA neurons needs to be studied in more detail.  
2.12 p27 deficiency maintains increased expression of cell cycle markers and neural 
precursors at later developmental stages 
Since we saw that the effects of p27 deficiency were maintained at E13.5 and E14.5, we next 
studied the cell cycle marker Ki67 and the neural progenitor marker Sox2. We saw that Ki67 
expression remained high at E13.5 (21.0% ± 5.1 expression in p27-/- mice compared to 9.9% 
± 4.4 in controls; p<0.05* and 1.61 ± 0.43 relative Ki67 E13.5 mRNA levels in p27-/- mice 
compared to 0.94 ± 0.26 in controls; p<0.05*; Figure 2.12 A-A”) and E14.5 (11.7 ± 3.8 Ki67+ 
cells in p27-/- mice compared to 3.1 ± 2.0 in controls; p<0.05* and 1.42 ± 0.23 relative Ki67 
E14.5 mRNA levels in p27-/- mice compared to 1.07 ± 0.29 in controls; p<0.05*; Figure 2.12 
B-B”). 
Figure 2.11: p27 deficiency alters the progression of DA neuron development. A-A’’) Coronal 
sections of E13.5 VM showing increased expression of Nurr1+TH- cells in p27 deficient mice 
compared to controls. B-B’’) Coronal sections of E13.5 VM showing decreased expression of 
Pitx3+TH+ double positive cells in p27 deficient mice compared to controls. Data represents mean ± 
S.E.M. (n=3 for each experiment). Statistical analysis was performed using Student’s t-test between 





Figure 2.12: p27 deficiency maintains increased expression of cell cycle markers and neural 
precursors at later developmental stages. A-A’) Coronal sections of E13.5 VM showing increased 
Ki67 expression in p27 deficient mice as compared to control and A”) increased Ki67 mRNA levels. 
B-B’) Coronal sections of E14.5 VM showing increased Ki67 expression in p27 deficient mice as 
compared to control and B”) increased Ki67 mRNA levels. C-C’) Coronal sections of E13.5 VM 
showing increased Sox2 expression in p27 deficient mice as compared to control and C”) increased 
Sox2 mRNA levels. D-D’) Coronal sections of E14.5 VM showing increased Sox2 expression in p27 
deficient mice as compared to control and D”) increased Sox2 mRNA levels.  Data represents mean ± 
S.E.M. (n=4-8 for each experiment). Statistical analysis was performed using Student’s t-test between 
control and p27 deficient mice; p<0.05*; p<0.01**. Scale bars = 50µm. 
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  Similar results were obtained for Sox2, where we again observed increased expression 
at E13.5 (20.0% ± 6.1 Sox2 expression in p27-/- mice compared to 9.1% ± 0.5 in controls; 
p<0.01** and 1.6 ± 0.3 relative Sox2 mRNA levels in p27-/- mice compared to 1.03 ± 0.29 in 
controls; p<0.05*; Figure 2.12 C-C”) and E14.5 (51.0 ± 7.1 Sox2+ cells in p27-/- mice 
compared to 27.3 ± 3.2 in controls; p<0.05* and 1.81 ± 0.66 relative Sox2 mRNA levels in p27-
/- mice compared to 1.09 ± 0.36 in controls; p<0.05*; Figure 2.12 D-D”).  
Furthermore, knowing that Ki67 and Sox2 are co-expressed almost 100% with the 
proliferation markers BrdU and PCNA, these results are an indirect measure of increased 
proliferation at later developmental stages, allowing us to conclude that p27 deficiency 
increases the pool of proliferating precursors in the midbrain throughout development.  
2.13 Effects of p27 deficiency on DA precursors are maintained at later developmental 
stages, but their distribution is recovered  
 When investigating the expression of Ngn2, we saw that at E13.5, the expression 
remained high (70.9 ± 8.1 Ngn2+ cells in p27-/- mice compared to 41.9 ± 2.2 in controls; 
p<0.0001**** and 1.23 ± 0.05 relative Ngn2 mRNA levels in p27-/- mice compared to 1.01 ± 
0.1 in controls; p<0.01**; Figure 2.13 A-A”). By E14.5, the expression of Ngn2 had 
disappeared in controls, whereas we observed some expression in p27 deficient mice (3.3 ± 1.5 
Ngn2+ cells in E14.5 p27-/- mice compared to 0.1 ± 0.1 in controls; p<0.05* and 1.57 ± 0.35 
relative Ngn2 mRNA levels in E14.5 p27-/- mice compared to 1.12 ± 0.31 in controls; p<0.05*; 
Figure 2.13 B-B”).  
 However, when looking at the distribution of DA neuron precursors, we saw that there 
was a trend indicating an increased level of Ngn2+Sox2+ double positive cells in E13.5 p27 
deficient mice compared to controls (26.3 ± 5.9 Ngn2+Sox2+ cells in p27-/- mice compared to 
15.3 ± 4 in controls; Figure 2.13 C,D), but this increase was not significant. Furthermore, we 
saw that the expression of Ngn2+Sox2+ cells in relation to total Sox2+ cells was recovered by 
E13.5 (14.5 ± 3 Ngn2+Sox2+/Total Sox2+ cells in p27-/- mice compared to 12.4 ± 3.1 in 
controls; Figure 2.13 D’). This led us to believe that perhaps the increased Ngn2+Sox2+ cells 
we saw at earlier stages had begun differentiating, and therefore, we initially expected to see a 
greater number of Ngn2+Sox2- cells in the IZ. However, like at earlier stages, we did not see 
an increase in the number of DA neuron precursors that had exited the cell cycle, making up 




Figure 2.13: Effects of p27 deficiency on DA precursors are maintained at later developmental 
stages, but their distribution is recovered. A-A’) Coronal sections of E13.5 VM showing increased 
Ngn2 expression in p27 deficient mice as compared to control and A”) increased Ngn2 mRNA levels. 
B-B’) Coronal sections of E14.5 VM showing increased Ngn2 expression in p27 deficient mice as 
compared to control and B”) increased Ngn2 mRNA levels. C) Coronal sections of E13.5 VM showing 
co-expression of Ngn2 and Sox2. D-D”) Quantification of Ngn2+Sox2+ double positive cells of the 
VZ and Ngn2+Sox2- cells of the IZ. Data represents mean ± S.E.M. (n=3 for each experiment). 
Statistical analysis was performed using Student’s t-test between control and p27 deficient mice; 
p<0.05*; p<0.01**; p<0.0001****. Scale bars = 50µm. 
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In summary, we have seen that p27 deficiency decreases early DA neuron production, which is 
maintained at later stages of development, though markers such as Nurr1 begin to recover by 
E13.5. Furthermore, we observed that p27 deficiency caused an increase in cell proliferation at 
E12.5, as measured by BrdU and PCNA. This was further supported by an increase in the 
expression of the cell cycle marker Ki67 and the neural precursor marker Sox2 at all 
developmental stages examined. Our results also showed an increase in DA neuron-specific 
precursors (as measured by Ngn2+Sox2+ cells), although their distribution was altered at early 
developmental stages. These results, therefore, indicate an important function of p27 in the 




























POSSIBLE MOLECULAR MECHANISMS OF P27 DEFICIENCY IN VIVO 
After seeing the effects of p27 deficiency in vivo from embryonic ages E11.5-E14.5, we decided 
to look at possible molecular mechanisms to explain these effects. This included studying the 
effects of p27 on cell death, phenotype specification, cell cycle alterations and possible 
downstream effects of DA neuron progenitor differentiation.  
3.1 p27 deficiency does not increase programmed cell death in vivo 
To study the effects of p27 deficiency on cell death in the developing midbrain, we first studied 
the expression of pyknotic nuclei, which are fragmented nuclei indicative of cell death. We did 
not detect the presence of pyknotic nuclei, and thereby no significant differences in the 
expression between p27 deficient mice and controls (Figure 3.1 A-D, top panels). To confirm 
these results, we performed a similar study, staining for the apoptotic marker activated-Casp3, 
and again, did not detect the presence of this marker, and thereby no significant differences in 
p27 deficient mice as compared to controls (Figure 3.1 A-D, bottom panels). Therefore, 
increased cell death did not appear to be the cause of decreased DA neuron development in p27 
deficient mice. 
3.2 p27 deficiency does not alter phenotype specification in the developing VM 
Since increased cell death did not appear to be present in p27 deficient brains, we thought 
perhaps p27 could be altering the phenotypic specification of DA neurons in the developing 
midbrain. We studied the expression of BIII-Tub as a neurogenesis marker and Gfap as a 
gliogenesis marker at E11.5 (early development) and E13.5 (late development). We saw no 
significant changes in the expression of BIII-Tub at E11.5 (64.1% ± 2.9 BIII-Tub expression in 
p27-/- mice as compared to 62.6% ± 5.2 BIII-Tub expression in controls) or at E13.5 (87.5% ± 
3.6 BIII-Tub expression in p27-/- mice as compared to 89.6 ± 0.5 in controls) (Figure 3.2 A,B 
top panels; A’,B’), indicating that p27 deficiency does not alter neurogenesis in the developing 
VM. When investigating the marker Gfap, we saw no expression and no significant differences 
at E11.5 or E13.5, indicating that p27 does not alter or accelerate gliogenesis (Figure 3.2 A,B 
bottom panels; A”,B”).    
 Seeing that the general processes of neurogenesis and gliogensis were not affected by 
p27 deficiency, we did a more in-depth analysis of the mRNA levels of specific neuronal 
phenotypes, both known to reside in the VM (such as GABA-ergic and glutamatergic neurons) 
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Figure 3.1: p27 deficiency does not increase programmed cell death in vivo. A-A”) Coronal 
sections of E11.5 VM showing an apparent absence of pyknotic nuclei (top panels) and activated-
Casp3 (bottom panels) in both p27 deficient mice and controls. Similar results were obtained at E12.5 
(B-B”), E13.5 (C-C”) and E14.5 (D-D”). Data represents mean ± S.E.M. (n=3 for each experiment). 
Statistical analysis was performed using Student’s t-test between control and p27 deficient mice. Scale 
bars = 50µm. 
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Figure 3.2: p27 deficiency does not alter cell fate specification. A-A”) Coronal sections of E11.5 
VM showing no differences in the expression of BIII-Tub (top panels) or Gfap (bottom panels) 
between p27 deficient mice and controls. Similar results were obtained at E13.5 (B-B”). RT-qPCR 
showing decreased TH mRNA levels (C) at E14.5 but no alterations in the mRNA levels of BIII-Tub 
(C’) or Gfap (C”). RT-qPCR showing no alterations in the mRNA levels of GABAergic (D), 
Glutamatergic (E) or Serotonergic (F) markers at E14.5. Data represents mean ± S.E.M. (n=4-8 for 
each experiment). Statistical analysis was performed using Student’s t-test between control and p27 
deficient mice; p<0.05*. Scale bars = 50µm. 
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and outside the VM (serotonergic neurons). First, we confirmed that there were decreased TH 
mRNA levels in p27 deficient mice compared to controls at E13.5, as well as no changes in the 
mRNA levels of BIII-Tub or Gfap (Figure 3.2 C-C”). Then we studied the GABAergic markers 
GABA and Gad1 (Figure 3.2 D), the glutamatergic markers Vglut2, Vglut1 and Glul (Figure 
3.2 E), and the serotonergic markers Sert1 and Tph2 (Figure 3.2 F), and saw no significant 
differences in the mRNA levels of either of these markers when comparing p27 deficient mice 
to controls. These results indicate that p27 deficiency does not alter cell fate specification and 
the effect appears to be specific to DA neurons.  
3.3 Effects of p27 deficiency on G1 phase cyclins and CDKs  
Since p27 is best known for its function in the cell cycle, we wanted to see how p27 deficiency 
affected different cyclins and CDKs. We first investigated the G1 phase cyclins D1, D2 and 
D3. Cyclin D1 mRNA levels were decreased in p27 deficient mice at early developmental 
stages (Figure 3.3 A-A’’’), whereas Cyclin D2 mRNA levels were decreased at later 
developmental stages (Figure 3.3 B-B’’’). Cyclin D3 mRNA levels showed somewhat 
inconsistent results, with no clear pattern or effect of p27 deficiency (Figure 3.3 C-C’’’). When 
studying the CDKs associated with these cyclins, we saw no significant effects of p27 
deficiency on Cdk4 (Figure 3.3 D-D’’’), but Cdk6 mRNA levels were significantly decreased 
in p27 deficient mice, especially at later developmental stages (Figure 3.3 E-E’’’).  
Since decreased Cyclin D levels are associated with longer cell cycles and the onset of 
differentiation (Bryja et al 2003), these results suggest that p27 deficiency decrease DA neuron 
development by shortening the cell cycle of these neurons despite decreased Cyclin D levels, 
most likely by affecting other parts of the cell cycle.  
3.4 Effects of p27 deficiency on G1-S and G2-M phase cyclins and CDKs 
The direct effect of p27 on promoting cell cycle exit lies in its function at the G1-S phase 
transition, where it inhibits Cyclin E/A-Cdk2 complexes. When studying the mRNA levels of 
Cyclin A, we saw significant increases in mRNA levels at all developmental stages studied 
Figure 3.4 A-A’’’). We obtained similar results for Cyclin E, showing increased mRNA levels 
at all stages, with the exception of E14.5 (Figure 3.4 B-B’’’). p27 deficiency caused a trend in 
slightly increasing Cdk2 mRNA levels during development, but these differences were only 
significant at E14.5. 
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Figure 3.3: Effects of p27 deficiency on G1 phase cyclins and CDKs. A-A’’’) Cyclin D1 mRNA 
levels from E11.5-E14.5. B-B’’’) Cyclin D2 mRNA levels from E11.5-E14.5. C-C’’’) Cyclin D3 
mRNA levels from E11.5-E14.5. D-D’’’) Cdk4 mRNA levels from E11.5-E14.5. E-E’’’) Cdk6  mRNA 
levels from E11.5-E14.5. Data represents mean ± S.E.M. (n=8 for each experiment). Statistical 
analysis was performed using Student’s t-test between control and p27 deficient mice; p<0.05*; 
p<0.01**; p<0.0001****.  
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Figure 3.4: Effects of p27 deficiency on G1-S and G2-M phase cyclins and CDKs. A-A’’’) Cyclin 
A mRNA levels from E11.5-E14.5. B-B’’’) Cyclin E  mRNA levels from E11.5-E14.5. C-C’’’) Cdk2 
mRNA levels from E11.5-E14.5. D-D’’’) Cyclin B mRNA levels from E11.5-E14.5. E-E’’’) Cdk1  
mRNA levels from E11.5-E14.5. Data represents mean ± S.E.M. (n=8 for each experiment). Statistical 
analysis was performed using Student’s t-test between control and p27 deficient mice; *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001.  
99 
 Finally, studying the G2-M phase transition, we again saw significant increases in 
Cyclin B mRNA levels at all developmental stages studied (Figure 3.4 D-D’’’). Again, when 
studying Cdk1, we see that p27 deficiency causes an increased trend during development, with 
significant differences at later developmental stages (Figure 3.4 E-E’’’).  
3.5 Effects of p27 deficiency on CKI inhibitors in the developing VM 
Since p27 is a member of the CKI family that also contains p57 and p21, we wanted to study 
how p27 deficiency affected the mRNA levels of these two CKIs. We saw a general pattern 
where p57 was significantly decreased in p27 deficient mice at early developmental stages but 
was recovered by E13.5 (Figure 3.5 A-A’’’’) and p21 was significantly increased in p27 
deficient mice at early developmental stages, but, again, was recovered by E13.5 (Figure 3.5 
B-B’’’). 
3.6 Screen of possible novel targets of Ngn2 in the developing VM 
Until now, we have seen that p27 deficiency significantly decreases DA neuron development 
but increases the production of DA neuron precursors. Furthermore, we have seen that these 
precursors are not undergoing cell death and they have not undergone altered phenotypic 
specification. The altered distribution of DA precursors (as measured by Ngn2+Sox2+) 
Figure 3.5: Effects of p27 deficiency on CKI inhibitors in the developing VM. A-A’’’) p57 mRNA 
levels from E11.5-E14.5. B-B’’’) p21 mRNA levels from E11.5-E14.5. Data represents mean ± S.E.M. 
(n=8 for each experiment). Statistical analysis was performed using Student’s t-test between control 
and p27 deficient mice; p<0.01**; p<0.001***. 
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suggests that p27 deficiency halts the differentiation of these double positive cells in a 
precursors state. We therefore did a screening of Ngn2-related factors, including known direct-
downstream targets. The first screen included Mash1, which has been known to cooperate with 
Ngn2 during DA neuron development (Kele et al 2006), and we saw a significant increase in 
mRNA levels at E12.5 in p27 deficient mice (1.35 ± 0.19 Mash1 mRNA levels) compared to 
controls (1.03 ± 0.26 Mash1 mRNA levels; p<0.05*; Figure 3.6 A). Next, we studied the 
expression of the progenitor maintenance markers Hes1, Hes5 and Dll1, thinking that p27 
deficiency halted DA neuron development by promoting a progenitor state. However, we saw 
no significant differences in the expression of any of these markers at E12.5 (Figure 3.6 B-D). 
Pax5, another important factor in DA neuron development, also appeared unaffected by p27 
deficiency (Figure 3.6 E).  
 Knowing that p27 deficiency did not appear to promote a progenitor state, we did a 
screen of NeuroD proteins, known downstream targets of Ngn2, that have been shown to 
promote neurogenesis in the retina (Cherry et al 2011) and inner ear (Boutin et al 2010). 
Interestingly, we saw a significant decrease in NeuroD1 mRNA levels at E12.5 in p27 deficient 
mice compared to controls (0.78 ± 0.12 NeuroD1 mRNA levels in p27-/- mice compared to 
Figure 3.6: Screen of possible novel targets of Ngn2 in the developing VM. RT-qPCR results from 
E12.5 showing A) increased Mash1 mRNA levels and unaltered Hes1 (B), Hes5 (C), Dll1 (D) and 
Pax5 (E) mRNA levels in p27 deficient mice compared to control. F-J) Screen of NeuroD1 proteins 
in the VM, of which NeuroD1 is of special interest, showing decreased mRNA levels in p27 deficient 
mice compared to controls (F). Data represents mean ± S.E.M. (n=8 for each experiment). Statistical 
analysis was performed using Student’s t-test between control and p27 deficient mice; p<0.05*; 
p<0.01**. 
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1.01 ± 0.14 in controls; p<0.01**; Figure 3.6 F), while the majority of other NeuroD proteins 
appeared unaffected (Figure 3.6 G-J). There was a significant increase in NeuroD4 mRNA 
levels (Figure 3.6 I), which should be studied in more detail, however due to previous work 
describing the role of NeuroD1 in neural tissue, and its relevance in neuronal differentiation, 
we did a deeper investigation of the possible role of NeuroD1 in DA neuron development.   
3.7 p27 deficiency decreases NeuroD1 in the developing VM 
We first studied the mRNA levels of Mash1 at all developmental stages, and saw significant 
increases at E11.5 to E13.5, but these increases recovered to control levels by 14.5. These 
results suggest a possible compensatory mechanism for p27 deficiency. Next, based on the 
results we obtained from our screen of downstream-Ngn2 targets, we did a deeper investigation 
of NeuroD1 expression in the developing midbrain. We saw that NeuroD1 mRNA levels were 
decreased at E11.5 (0.71 ± 0.15 relative NeuroD1 mRNA levels in p27-/- mice compared to 
1.01 ± 0.14 in controls; p<0.05*; Figure 3.7 B), at E12.5 (mentioned above, Figure 3.7 B’), at 
E13.5 (0.79 ± 0.13 relative NeuroD1 mRNA levels in p27-/- mice compared to 1.01 ± 0.17 in 
controls; p<0.05*; Figure 3.7 B”), and these differences recovered by E14.5 (0.93 ± 0.19 
relative NeuroD1 mRNA levels in p27-/- mice compared to 1.03 ± 0.14 in controls; Figure 3.7 
B’’’). These results were confirmed in brain sections at early developmental stages, where we 
again saw a significant decrease in NeuroD1 expression at E11.5 in p27 deficient mice (9.3 ± 
4.5 NeuroD1+ cells in p27-/- mice compared to 57.0 ± 2.0 in controls; p<0.0001****; Figure 
3.7 C) and E12.5 (19.7 ± 8.5 NeuroD1+ cells in p27-/- mice compared to 52.7 ± 11.9 in controls; 
p<0.05*; Figure 3.7 D). We also observed that the decreased expression of NeuroD1 was almost 
completely absent from the ventral most part of the IZ in the VM, with an expression pattern in 
p27 deficient mice restricted to a more lateral position (Figure 3.7 B). Furthermore, since 
NeuroD1 has not yet been described in the context of the developing VM, we investigated if 
NeuroD1 was co-expressed with TH. We saw no NeuroD1+TH+ double positive cells in p27 
deficient or control mice (Figure 3.7 C,D bottom panels), indicating that the function of 
NeuroD1 is most likely upstream of TH.  
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Figure 3.7: p27 deficiency decreases NeuroD1 in the developing VM. A-A’’’) RT-qPCR results 
showing increased Mash1 mRNA levels from E11.5-E14.5. B-B’’’) RT-qPCR results showing 
decreased NeuroD1 mRNA levels from E11.5-E14.5. C,C’) Coronal sections of E11.5 VM showing 
decreased NeuroD1 and C”) no co-expression with TH. D,D’) Coronal sections of E12.5 VM showing 
decreased NeuroD1 and D”) no co-expression with TH in p27 deficient mice compared to controls. 
Data represents mean ± S.E.M. (n=4-8 for each experiment). Statistical analysis was performed using 





Figure 3.8: Description of possible importance of NeuroD1 in the developing VM. A-A’’) Coronal 
sections of E11.5 VM showing decreased expression of NeuroD1+/Ngn2+ double positive cells in p27 
deficient mice compared to controls. B-B’’) Coronal sections of E12.5 VM showing decreased 
expression of NeuroD1+/Ngn2+ double positive cells in p27 deficient mice compared to controls. C-
C’’) Coronal sections of E11.5 VM showing expression pattern of NeuroD1 and p27 in control mice. 
D-D’’) Coronal sections of E12.5 VM showing expression pattern of NeuroD1 and p27 in control 
mice. Data represents mean ± S.E.M. (n=3 for each experiment). Statistical analysis was performed 
using Student’s t-test between control and p27 deficient mice;  p<0.01**; p<0.001***; p<0.0001****. 
Scale bars = 50µm. 
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3.8 Description of possible importance of NeuroD1 in the developing VM 
Although we saw no co-expression of NeuroD1 with TH, we studied the expression of NeuroD1 
with upstream factor Ngn2 and saw some co-expression of these two factors in controls at E11.5 
(20.1 ± 1.0 NeuroD1+Ngn2+ cells), which was significantly decreased in p27 deficient mice 
(4.3 ± 1.5 NeuroD1+Ngn2+ cells; p<0.0001****; Figure 3.8 A-A’). These results were 
confirmed at E12.5 (6.3 ± 1.5 NeuroD1+Ngn2+ cells in p27-/- mice compared to 17.3 ± 2.1 in 
controls; p<0.01**; Figure 3.8 B-B’). When studying NeuroD1+Ngn2+ cells in relation to the 
total Ngn2+ cells, we also see that the majority of NeuroD1+ cells are in the IZ, which is 
diminished in p27-/- mice (3.1 ± 0.8 NeuroD1+Ngn2+/Total Ngn2+ cells in p27-/- mice 
compared to 17.4 ± 3.2 in controls at E11.5; p<0.01**; Figure 3.8 A” and 7.3 ± 1.6 
NeuroD1+Ngn2+/Total Ngn2+ cells in p27-/- mice compared to 25.9 ± 6.4 in controls at E12.5; 
p<0.01**; Figure 3.8 B”). Seeing the distribution of NeuroD1 in the IZ, we did a study of the 
expression pattern of NeuroD1 with p27, and saw a similar pattern as seen with Ngn2 earlier. 
However, in the case of NeuroD1, about 30% of NeuroD1+ cells were p27+NeuroD1+ double 
positive at E11.5, which raised to about 35% at E12.5 (Figure 3.8 C,D). These results strongly 
suggest an important function of NeuroD1 in the cascade of proper signaling to generate mature 
DA neurons, which could describe a novel factor linking Ngn2 and TH.  
 
In summary, we have shown that p27 deficiency does not decrease DA neuron development by 
increasing cell death or altering phenotypic specification in vivo. Furthermore, we have seen a 
general effect of p27 deficiency on the cell cycle, showing increased mRNA levels of Cyclin 
A, Cyclin E and Cdk2, consistent with the effects observed for increased proliferation. Finally, 
in an attempt to explain how we see more proliferation and a greater number of DA neuron 
precursors, but an overall decrease in DA neuron development, we studied direct downstream 
targets of Ngn2. We saw a significant decrease in the expression of NeuroD1, a novel factor in 
the context of the VM, which could explain a cell-cycle independent function of p27, where the 
absence of p27 may hinder the proper progression of DA neuron development by affecting the 








EFFECTS OF P27 DEFICENCY ON VM PRIMARY CULTURES 
Although p27 has previously been associated with increased cell death (Bryja et al 2004, Bryja 
et al 2005), we did not observe such effects in tissue sections from the VM. Therefore, we 
decided to dissect the VM of E13.5 embryos, manually dissociate and seed the cells to see if 
p27 deficiency had an effect on the differentiation of VM primary cultures. 
 
4.1 p27 deficiency decreases DA neurons in VM primary cultures 
We first studied the effects of p27 deficiency on TH expression, and saw that in p27 deficient 
cultures there was a significant decrease (2.13% ± 0.73 TH+ cells/Hoe) compared to controls 
(7.31% ± 1.44 TH+ cells/Hoe; p<0.01*; Figure 4.1 B,C). These results were supported by 
decreased Nurr1 expression in p27 deficient cultures (3.18% ± 1.08 Nurr1+ cells/Hoe) 
compared to controls (12.03% ± 0.28 Nurr1+ cells/Hoe; p<0.001***; Figure D,E). These results 
confirm our previous results that p27 deficiency decreases DA neuron production.  
 
4.2 p27 deficiency increases mitotic precursors in VM primary cultures 
We next studied the effects of p27 on the cell cycle marker Ki67 and the neural precursor marker 
Sox2. In line with our previous results, we saw a significant increase in both Ki67 (46.1% ± 7.0 
Ki67+ cells/Hoe in p27-/- cultures compared to 20.0% ± 5.1 in controls; p<0.01**; Figure 4.2 
A-A’) and Sox2 (23.6% ± 5.6 Sox2+ cells/Hoe in p27-/- cultures compared to 11.8% ± 3.0 in 
controls; p<0.05*; Figure B-B’). 
 
4.3 p27 deficiency increases cell proliferation in VM primary culture 
To study the effects of p27 deficiency on proliferation in primary cultures, we treated the cells 
with BrdU for 4 hours before fixing the cells in 4% PFA. We saw that p27 deficient cultures 
had a significant increase in BrdU expression (47.4% ± 7.9 BrdU+ cells/Hoe) compared to 
controls (11.9% ± 4.5 BrdU+ cells/Hoe; p<0.01**; Figure 4.3). These results support our 
previous findings that p27 deficiency increases cell proliferation.  
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4.4 DA neurons appear immature in p27 deficient VM primary cultures 
One effect that became apparent in primary cultures was that the aspect of TH+ DA neurons 
appeared much more immature than control cells. To quantify this, we counted the total number 
of dendrites on at least 50 TH+ DA neurons per group, and the average length of those dendrites. 
We saw that in p27 deficient cultures, the average number of dendrites per TH+ neuron was 1.5 
± 0.12 compared to 2.2 ± 0.16 in controls (p<0.0001****; Figure A,B). The average length of 
dendrites in p27 deficient cultures was 21.6µm ± 0.1 compared to 77.5µm ± 3.4 in controls 
(p<0.0001****; Figure A,C). These results suggest that although TH+ cells are present in p27 
deficient cultures, these neurons appear more immature.  
Figure 4.1: p27 deficiency decreases DA neurons in VM primary cultures. A) Diagram of 
differentiation protocol followed. B,C) ICC showing decreased TH+ neurons in p27 deficient primary 
cultures compared to control. D,E) ICC showing decreased Nurr1+ neurons in p27 deficient primary 
cultures compared to control. Data represents mean ± S.E.M. (n=3  for each experiment). Statistical 
analysis was performed using Student’s t-test between control and p27 deficient cultures; p<0.01**; 




Figure 4.3: p27 deficiency increases cell proliferation in VM primary cultures. A,B) ICC showing 
increased BrdU+ cells in p27 deficient primary cultures compared to control. Data represents mean ± 
S.E.M. (n=3 for each experiment). Statistical analysis was performed using Student’s t-test between 
control and p27 deficient cultures; p<0.01**. Scale bars = 50µm. 
 
Figure 4.2: p27 deficiency increases mitotic precursors in VM primary cultures. A,A’) ICC showing 
increased Ki67+ cells in p27 deficient primary cultures compared to control. B,B’) ICC showing 
increased Sox2+ cells in p27 deficient primary cultures compared to control. Data represents mean ± 
S.E.M. (n=3 for each experiment). Statistical analysis was performed using Student’s t-test between 




Figure 4.4: DA neurons appear immature in p27 deficient VM primary cultures. A) ICC showing 
general aspect of TH+ neurons. B) Quantification of average dendrite length in p27 deficient cultures 
compared to control. C) Quantification of average number of dendrites per TH+ neuron. Data 
represents mean ± S.E.M. (n=3 for each experiment, and at least 50 neurons were counted per n). 
Statistical analysis was performed using Student’s t-test between control and p27 deficient cultures; 
p<0.0001****. Scale bars = 50µm. 
 
109 
In summary, we saw that p27 deficient primary cultures had decreased TH+ and Nurr1+ DA 
neurons, and these neurons appeared more immature (quantified by dendrite number and 
length). p27 deficient primary cultures also showed an increased pool of proliferating 
precursors. These results support our previous result in vivo, showing that p27 has an important 








EFFECTS OF P27 ON DA NEURON DEVELOPMENT IN VITRO 
To study the effects of p27 on DA neuron development in vitro, we generated several different 
cell lines, that we later used to manipulate p27 expression levels, which allowed us to study the 
effects of p27 deficiency, p27 recovery and p27 overexpression. Based on the results we 
obtained for NeuroD1, we also generated a cell line where we ectopically expressed NeuroD1 
in p27 deficient cells in order to see if any effect could be recovered.  
5.1 Generation and characterization of p27-deficient mouse iPSCs 
5.1.1 Generation of p27-deficient mouse iPSCs 
To generate p27-deficient miPSCs, we nucleofected MEFs extracted from E13.5 embryos 
with the CoMIP plasmid containing the four pluripotency genes Sox2, Oct4, Klf4 and c-Myc as 
described in materials and methods, and according to the schematic in Figure 5.1.1 A. The 
efficiency of this nucleofection was confirmed by co-nucleofecting the CoMIP plasmid with 
GFP to quantify the green cells, indicative of successful nucleofection. We saw a nucleofection 
efficiency of approximately 30-40% in both control and p27-/- MEFs (Figure 5.1.1 B-C). MEFs 
Figure 5.1.1 Generation of p27-deficient mouse iPSCs A) Diagram of reprogramming protocol. B) 
Phase contrast images of MEFs after nucleofection (top panels) and cells that have incorporated the 
reprogramming plasmid as indicated by co-transfection with GFP (bottom panels). C) Nucleofection 
efficiency. D) CoMIP plasmid structure (Diecke et al 2015). Scale bars = 50µm. 
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from p27-/- embryos E13.5(1) and E13.5(9) were reprogrammed to become miPSC p27KO(1) 
and miPSC p27KO(9), respectively. MEFs from p27+/+ embryos were reprogrammed to 
become miPSC WT controls. 
5.1.2 Characterization of miPSCs in proliferation 
When reprogramming adult somatic cells such as MEFs to a pluripotent state, it is essential 
to confirm the pluripotency of these cells. We first confirmed that the morphology of our 
proliferating miPSC WT, p27KO(1) and p27KO(9) cells were identical to R1 mESC control 
cells (Figure 5.1.2 A). Next, we studied the basal expression of the pluripotency markers Sox2, 
Figure 5.1.2 Characterization of miPSCs in proliferation A) Phase contrast images comparing 
morphology of reprogrammed cells to R1 control cells and MEFs as negative control. B) RT-qPCR 
showing mRNA levels of the pluripotency genes Sox2, Oct4, Klf4 and Nanog. C) WB showing protein 
expression of Sox2 and Oct4. D) ICC showing expression of pluripotency genes. Scale bars = 50µm. 
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Oct4 and Klf4 (all from the original plasmid) and Nanog (not present in the reprogramming 
plasmid). We confirmed mRNA expression via RT-qPCR experiments and protein expression 
via WB and ICC experiments (Figure 5.1.2 B-D).  
5.1.3 Characterization of miPSCs in differentiation 
Another important characteristic of pluripotent stem cells is their ability to differentiate to 
the three germ layers (endoderm, mesoderm and ectoderm). We therefore seeded embryoid 
bodies and left these cells in a non-specified differentiation medium to allow the cells to 
differentiate spontaneously, and later stained for Afp (endoderm), α-actin (mesoderm) and BIII-
Figure 5.1.3 Characterization of miPSCs in differentation A) ICC showing expression of all three 
germ layers after spontaneous differentiation of EBs. RT-qPCR showing mRNA levels of endoderm 
markers (B), mesoderm markers (C) and ectoderm markers (D). Scale bars = 50µm.  
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Tub (ectoderm) to ensure the differentiation potential of these cells (Figure 5.1.3 A). We 
confirmed these results by RT-qPCR experiments (Figure 5.1.3 B-D). 
5.2 p27 deficiency decreases directed differentiation of DA neurons in vitro 
Once we established that our MEFs had been properly reprogrammed and that they presented 
the necessary traits of pluripotency, we wanted to see if there were specific effects of p27 
deficiency on the directed differentiation of these miPSCs towards a DA phenotype, following 
the protocol described in Figure 5.2 A. We first studied the expression of BIII-Tub, and saw no 
significant differences between WT control and p27KO cultures (Figure 5.2 B,C). Next, we 
studied the expression of TH+ colonies, where we counted the total number of colonies 
expressing at least 100 TH+ cells, compared to total number of colonies (measured by Hoescht).  
We saw a significant decrease in TH+ colonies in p27 deficient cultures compared to control 
(87.9% ± 3.9 TH+ colonies in WT cultures compared to 25.1% ± 25.0 TH+ colonies in 
p27KO(1) cultures, p<0.01**; and 34.1% ± 7.21 TH+ colonies in p27KO(9) cultures, 
p<0.0001****; Figure 5.2 B,C). Furthermore, when counting TH+ cells per area, we observed 
significant decreases in p27KO(1) and p27KO(9) cultures compared to control (Figure 5.2 
B,C). We confirmed these results with RT-qPCR studies, with a clear trend consistent with our 
in vivo results, showing decreased TH, Nurr1 and Pitx3 levels and increased Ki67, Sox2 and 
Ngn2 levels, and these differences reached significant levels in p27KO(1) cultures (Figure 5.2 
D). It is important to note that NeuroD1 levels were also significantly decreased in p27KO(1) 
cultures, which supports our earlier claim that it may be a novel factor important for proper DA 
neuron development. 
5.3 Generation of p27KOp27 recovery mouse iPSCs 
After seeing the effects of p27 deficiency in vitro (which corroborated our in vivo results), we 
wanted to see if we could recover some of these effects by re-introducing p27 into the deficient 
cells (Figure 5.3). We did this by nucleofecting the plasmid pBabep27 into p27KO(1) and 
p27KO(9) cells, using the empty pBabe vector as a control. KO(1) cells show a lower 
nucleofection efficiency of around 20%, while KO(9) cells had an efficiency of around 40% 
(Figure 5.3 B,C). After two weeks of puromycin selection, the cells were subjected to a limiting 
dilution protocol to isolate individual cells, thereby forming homogenous clones.     
p27KO(1)p27 recovery Clones 4 and 5, as well as  p27KO(9)p27 recovery Clones 2 and 5 were selected 
for further experiments based on p27 expression detected by WB (Figure 5.3 D,E).  
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Figure 5.2: p27 deficiency decreases directed differentiation of DA neurons in vitro.  A) 
Differentiation protocol followed. B) ICC showing decreased TH+ colonies and TH+ cells/area in p27KO 
miPSCs compared to controls C) Quantification of ICC. D) RT-qPCR results comparing the mRNA levels 
of TH, Nurr1, Pitx3, Ki67, Sox2, Ngn2 and NeuroD1 in p27KO miPSCs to controls. Data represents mean 
± S.E.M. (n=3 for each experiment, and at least 3 wells were quantified per n). Statistical analysis was 
performed using ANOVA between WT, p27KO(1) and p27KO(9) cell lines; p<0.05*; p<0.01**; 




5.4 p27 recovery improves directed differentiation of DA neurons in vitro 
We next wanted to see the effects of p27 recovery on the directed differentiation of our p27KO 
miPSCs towards a DA phenotype, following the protocol described in Figure 5.4 A. We first 
studied the expression of BIII-Tub+ colonies in relation to Hoescht+ colonies, and to our 
surprise, saw a significant decrease in the total number of BIII-Tub colonies in p27 recovery 
cells compared to p27 deficient controls (Figure 5.4 B-D). However, this result should be 
investigated in more detail by, for example, studying total number of BIII-Tub/area or 
quantifying the aspect of these positive colonies. Next, we studied the expression of TH+ 
colonies, where we counted the total number of colonies expressing at least 100 TH+ cells 
compared to total number of colonies (measured by Hoescht).  We saw a partial recovery, and  
Figure 5.3 Generation of p27KOp27 recovery miPSCs A) Diagram of reprogramming protocol. B) Phase 
contrast images of miPSCs after nucleofection (top panels) and cells that have incorporated the 
reprogramming plasmid as indicated by co-transfection with GFP (bottom panels). C) Nucleofection 
efficiency. D) WB confirming p27 expression and p27KO(1)p27 recovery clones selected. D) WB 




Figure 5.4: p27 recovery improves directed differentiation of DA neurons A) Differentiation 
protocol followed. B) ICC showing increased TH+ colonies in p27KOp27 recovery miPSCs compared to 
p27KO controls. C-D) Quantification of ICC. E) RT-qPCR results comparing the mRNA levels of TH, 
Nurr1, Pitx3, Ki67, Sox2, Ngn2 and NeuroD1 in p27KOp27 recovery miPSCs to p27KO controls. Data 
represents mean ± S.E.M. (n=3 for each experiment, and at least 3 wells were quantified per n). 
Statistical analysis was performed using ANOVA between p27KO control and p27KOp27 recovery clones 
for ICC analysis or Student’s t-test between p27KO(1) control and  p27KO(1)p27 recovery Clone 4 for 
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there was a clear trend indicating increased TH+ colonies in p27KOp27 recovery cultures compared 
to p27KO control, where p27KO(1)p27 recovery Clone 4 and p27KO(9)p27 recovery Clone 5 showed 
significant increases (55.0% ± 7.1 TH+ colonies in p27KO(1)27 recovery Clone 4 compared to 
20.1% ± 0.1 in p27KO(1) control; p<0.05* and 42.5% ± 2.7 TH+ colonies in KO(9)p27 recovery 
Clone 5 compared to 31.5% ± 5.7 in p27KO(9) control; p<0.01**; Figure 5.4 B-D). No 
significant differences were observed between p27KOp27 recovery clones, supporting the trend of 
increased TH+ colonies (Figure 5.4 C,D). These results were supported by RT-qPCR 
experiments, where p27KO(1)p27 recovery Clone 4 showed a partial recovery of DA neuron 
markers when compared to p27KO(1) control cultures (Figure 5.4 E). 
5.5 Generation of p27 overexpressing mouse PSCs 
After seeing the effects of p27 recovery in vitro, we wanted to see the effects of directly 
overexpressing p27 into R1 mESC and miPSC WT control cells. We did this by nucleofecting 
the plasmid pBabep27 into R1 and WT cells, using the empty pBabe vector as a control. R1 
mESCs showed a lower nucleofection efficiency of around 25%, while miPSC WT had an 
efficiency between 40-45% (Figure 5.5). After two weeks of puromycin selection, the cells 
were subjected to a limiting dilution protocol to isolate individual cells, thereby forming 
homogenous clones. R1 mESCp27 overexpression Clones 1 and 4, while miPSC WTp27 overexpression 
Clones 5 and 6 were selected for further experiments based on p27 expression detected by WB 
(Figure 5.5 D,E).  
5.6 p27 overexpression increases directed differentiation of DA neurons 
We next wanted to see the effects of p27 overexpression on the directed differentiation of these 
cells towards a DA phenotype, following the protocol described in Figure 5.6 A. We first 
studied the expression of BIII-Tub, and saw no significant differences in the total number of 
BIII-Tub colonies in R1 mESCp27 overexpression cells compared to R1 mESC controls (Figure 5.6 
B,C). Next, we studied the expression of TH+ colonies, where we counted the total number of 
colonies expressing at least 100 TH+ cells compared to total number of colonies (measured by 
Hoescht). Interestingly, we saw a significant increase in the number of TH+ colonies in              
R1 mESCp27 overexpression cultures (51.6% ± 7.7 TH+ colonies in R1 mESC control cultures 
compared to 82.7% ± 6.38 in R1 mESCp27 overexpression Clone 1; p £ 0.01** and 84.2% ± 2.11           
R1 mESCp27 overexpression Clone 4; p £ 0.01**; Figure 5.6 B,C). RT-qPCR studies confirmed this 
increase in TH expression, while also indicating an increase in both Ngn2 and NeuroD1 mRNA 
levels, supporting our previous results (Figure 5.6 D). 
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Figure 5.5 Generation of p27-overexpressing mPSCs A) Diagram of reprogramming protocol. B) 
Phase contrast images of mPSCs after nucleofection (top panels) and cells that have incorporated the 
reprogramming plasmid as indicated by co-transfection with GFP (bottom panels). C) Nucleofection 
efficiency. D) WB confirming p27 expression and R1 mESCp27 overexpression clones selected. D) WB 




Figure 5.6: p27 overexpression increases the directed differentiation of DA neurons. A) 
Differentiation protocol followed. B) ICC showing increased TH+ colonies and TH+ cells/area in p27 
overexpressing cells compared to control. C) Quantification of ICC. D) RT-qPCR results comparing 
the mRNA levels of TH, Nurr1, Pitx3, Ki67, Sox2, Ngn2 and NeuroD1 in R1 mESCp27 overexpression cells 
to controls. Data represents mean ± S.E.M. (n=3 for each experiment, and at least 3 wells were 
quantified per n). Statistical analysis was performed using ANOVA between R1 mESC control and 
R1 mESCp27 overexpression Clones 1 and 4 for ICC analysis or Student’s t-test between R1 mESC control 
and R1 mESCp27 overexpression Clone 4 for RT-qPCR analysis; p<0.05*; p<0.01**. Scale bars = 50µm. 
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5.7 Generation of p27KONeuroD1 mouse iPSCs 
Based on the results of NeuroD1 observed in vivo, we wanted to see if we could directly recover 
the effects of p27 deficiency by expressing NeuroD1 in p27 deficient cells. We did this by 
nucleofecting the plasmid pCX-NeuroD1 into p27KO(1) cells, using the empty pCX vector as 
a control. These cells showed a nucleofection efficiency of around 80% (Figure 5.7 B,C). After 
two weeks of neomycin selection, the cells were subjected to a limiting dilution protocol to 
isolate individual cells, thereby forming homogenous clones. p27KO(1)NeuroD1 Clones 7 and 9 
were selected for further experiments based on NeuroD1 expression detected by WB (Figure 
5.7 B,C).  
 
Figure 5.7 Generation of p27KONeuroD1 miPSCs A) Diagram of reprogramming protocol. B) Phase 
contrast images of miPSCs after nucleofection (top panels) and cells that have incorporated the 
reprogramming plasmid as indicated by co-transfection with GFP (bottom panels). C) Nucleofection 





5.8 Effects of NeuroD1 expression in p27 deficient miPSCs on DA neuron development 
We performed the same experiment as before, differentiating the cells according to the diagram 
in Figure 5.8 A. When investigating the effects of NeuroD1 expression in p27 deficient cells 
on BIII-Tub expression, we saw no significant differences in BIII-Tub+ colonies in relation to 
Hoescht between p27KONeuroD1 cultures and p27KO controls (Figure 5.8 B,C). However, when 
investigating the effects of NeuroD1 expression in p27 deficient cells on TH production, we 
saw a significant increase in TH+ colonies in relation to Hoescht, in both clones selected (36.6% 
± 4.7 TH+ colonies in p27KO control cultures compared to 71.3% ± 6.6 in p27KONeuroD1    
Clone 7; p<0.05* and 65.7% ± 5 p27KONeuroD1 Clone 9; p<0.05*; Figure 5.8 B,C). These results 
strongly support our previous results and suggest that p27 deficiency decreases DA neuron 
development by affecting NeuroD1. However, these results are preliminary, and more 
experiments are needed to confirm interactions between p27 and NeuroD1 as well as NeuroD1 
with TH.  
 
Figure 5.8: Effects of NeuroD1 expression in p27KO miPSCs on DA neuron development. A) 
Differentiation protocol followed. B) ICC showing unaltered BIII-Tub expression and increased TH+ 
colonies in p27KONeuroD1 miPSCs compared to p27KO controls. C) Quantification of ICC. Data 
represents mean ± S.E.M. (n=2 for each experiment, and at least 3 wells were quantified per n). 
Statistical analysis was performed using ANOVA between p27KO control cells and p27KONeuroD1 




In summary, we have shown a link between p27 expression and DA development, indicating 
an important function of p27 in this process. We have shown that p27 deficient cells produce 
less TH+ colonies and less TH+ cells/area as compared to control cells, indicating that p27 
deficiency decreases DA neuron development in vitro. This effect was supported by re-
introducing p27 into p27 deficient cells, which showed a partial recovery in the differentiation 
of DA neurons. Since we saw a partial recovery, we decided to investigate the effect of p27 
overexpression in control cells, and, interestingly, saw increased DA neuron development as 
quantified by increased TH+ colonies and TH+ cells/area in these cells. Finally, our preliminary 
results of NeuroD1 expression in p27 deficient cells also suggest a mechanism whereby p27 































Parkinson’s Disease is the second most common neurodegenerative disease affecting a 
steadily increasing number of people, which could reach 9.3 million cases worldwide by 2030 
(Dorsey et al 2007). Treatment options have been developed that can be highly effective in 
treating primary motor symptoms in certain patients (Fox et al 2018). However, despite decades 
of excellent research, there is still no cure for this disease. Therefore, PD has become an intense 
area of research in an attempt to find new, alternative treatment options that can lessen, halt or 
even reverse the pathological progression of this disease.  
The primary objective of this thesis has been to study the complex process of DA neuron 
development, in an attempt to find new and novel markers that could be useful in the 
development of alternative treatment options, such as stem cell replacement therapies. This 
process is tightly coordinated and based on the time-sensitive expression of several factors in 
specific contexts, making it an exceptionally complicated process to replicate in vitro. Our 
results provide novel evidence for the importance of p27 in the development of DA neurons, 
which in the context of the VM was seen to increase the pool of neural progenitors and affected 
the expression of Ngn2, where both p27 and Ngn2 are important and necessary for proper cell 
cycle exit followed by the onset of neurogenesis (Ohnuma and Harris 2003, Guillemot 2007, 
Kaldis and Richardson 2012). In an attempt to find the mechanistic action of p27, we saw 
interesting results for NeuroD1, where our preliminary results suggest an important novel 
function in the context of DA neuron development. Below we discuss our findings and suggest 
the importance of p27 via Ngn2 and NeuroD1, as possible key factors in the context of the VM 
that could help improve the development of DA neurons in vitro, and its potential application 
in PD.  
p27 Expression Pattern in the Developing VM 
  Before studying the effects of p27, we first determined if p27 was present in the 
midbrain, and next established its expression pattern in the developing VM. Previous work had 
originally shown that p27 was not present in the midbrain (Joseph et al 2003). However, these 
results were initially contradicted by a study showing that p27 gain of function promoted VM 
neurosphere differentiation (Sacchetti et al 2009), supported by another study showing that p27 
directly promoted neurogenesis in the cortex via Ngn2 (Nguyen et al 2006).  
 We therefore investigated the expression of p27 by RT-qPCR and WB experiments, and 
saw in both cases, that p27 was expressed as early as E11.5, and this expression increased with 
the development of the brain. These results are expected, since p27 is exclusively expressed in 
post-mitotic cells. We see a direct relationship between the number of proliferating precursors 
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(early development) with low p27 expression, as well as a direct relationship between the 
number of post-mitotic precursors and mature neurons (late development) with high p27 
expression.  
 We next performed IHC studies to see how p27 was distributed in the developing VM. 
We know DA neuron development begins in the floor plate of the VM (Arenas et al 2015), a 
region making up the VZ, consisting mainly of proliferating precursors (Ono et al 2007, La 
Manno et al 2016). As development progresses, these precursors begin to migrate and become 
post-mitotic, making up the IZ (Wallén et al 1999). These cells continue to migrate as they 
gradually begin losing progenitor identity while simultaneously gaining mature DA neuron 
identity, and are considered fully mature upon reaching the MZ (Ang 2006). Therefore, our 
results confirm that p27 expression corresponds to the expression of post-mitotic precursors in 
the IZ and mature neurons in the MZ and is absent from the VZ made up of mitotic precursors.  
 Due to the complexity of DA neuron development, we simplified the process by looking 
at five main stages, as defined by key markers important in these specific processes: TH, Nurr1 
and Pitx3 to study DA neuron identity, Foxa2 to study regionalization, Lmx1a to study 
specification, Ngn2 to study DA neurogenesis and the markers Ki67 (cell cycle) and Sox2 
(neural precursors) to study p27-related effects (Figure D.1). 
Figure D.1: Simplified diagram of DA neuron development. In order to perform a comprehensive 
study of the effects of p27 deficiency on DA neuron development, we simplified the process by studying 
markers representative of five main stages: DA neuron identity, regionalization, specification, general 





We first studied p27 expression with DA neuron identity markers. Nurr1 is the first 
post-mitotic DA neuron marker and is expressed in the IZ and MZ (Zetterström et al 1997, 
Wallén et al 1999, Kadkhodaei et al 2009), whereas TH and Pitx3 are markers of mature DA 
neurons, present mainly in the MZ (Smidt et al 2000, Smidt et al 2004, Ang 2009, Li et al 2009). 
These markers were almost exclusively co-expressed with p27, supporting our previous 
conclusion that p27 is expressed in the IZ and MZ, and further suggests a possible function of 
p27 in the development of these neurons.  
We next studied the expression of p27 with the regionalization marker Foxa2 and the 
specification marker Lmx1a, as representative markers of these two early developmental 
processes. However, it should not be forgotten that both factors coordinate the expression of 
several more genes (Prakash and Wurst 2006, Ang 2009, Arenas et al 2015), all important for 
DA neuron development. We detected both Foxa2 and Lmx1a expression in the VZ, and these 
markers were also co-expressed with p27 in the IZ and MZ, effectively demonstrating an 
expression pattern spanning all three developmental zones.   
We studied the expression of p27 with more general markers related to the cell cycle 
(Ki67, Sun and Kaufman 2018) and the expression of neural precursors (Sox2, Graham et al 
2003). We saw that both of these markers were restricted to the region lining the ventricle and 
was entirely complementary to p27 expression. These results are expected, as the expression of 
Ki67 or Sox2 with p27 would be mutually exclusive based on their expression profiles. Since 
Ki67 and Sox2 show the expression pattern of mitotic precursors, it becomes a way to measure 
the area of the VZ as development progresses and our study shows a steady decrease in the size 
of the VZ at later developmental stages. Whether p27 is responsible for inhibiting the 
expression of these markers, or if the downregulation of these markers by other mechanisms 
allows for the expression of p27 needs to be investigated in further detail, though it has been 
shown that p27 can repress the expression of Sox2 in differentiating ESCs (Li et al 2012).  
Finally, the importance of Ngn2 in the onset of neurogenesis of DA neurons has been 
previously described (Andersson et al 2006a, Kele et al 2006). Therefore, we studied the 
expression of Ngn2 with p27, and saw that the majority of Ngn2+ cells was mainly distributed 
throughout the VZ. A few Ngn2+ cells were found outside the VZ, interspersed, but not co-
expressed with, p27+ cells, which defines the region of the IZ. This suggests a regulatory role 
of p27 in the expression of Ngn2, but the exact interaction between p27 and Ngn2 in the VM 
needs to be studied in further detail.  
In summary, we have defined an expression pattern for p27 in the developing midbrain, 
and along with markers representative of important stages of differentiating DA neurons, have 
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been able to define and study the three developmental zones in relation to p27 expression under 
normal conditions (Figure D.2).  
Effects of p27 on DA neuron development  
We saw a dramatic decrease in the early production of TH+, Nurr1+ and Pitx3+ neurons 
in p27 deficient mice as compared to controls. These results were supported by in vitro 
experiments, where p27 deficient primary cultures and p27 deficient miPSCs produced fewer 
TH+ colonies and fewer TH+ cells/area as compared to controls under the same differentiation 
conditions. These results therefore indicate an important function of p27 in the initial production 
of DA neurons and confirm our main hypothesis, that p27 deficiency significantly decreases 
DA neuron production, in vivo and in vitro.   
Following a similar process as described above, we did an initial study of the effect of 
p27 deficiency on regionalization (Foxa2), specification (Lmx1a), p27-related effects (Ki67 
and Sox2) and neurogenesis (Ngn2). We saw that p27 did not affect the expression of Foxa2 or 
Lmx1a, suggesting that p27 may decrease DA neuron development by affecting the 
developmental process after the establishment of early regionalization (Ferri et al 2007, 
Kittappa et al 2007, Arenas 2008, Chung et al 2009) and specification (Andersson et al 2006b, 
Chung et al 2009, Yan et al 2011). This was contrary to what we originally expected, since we 
believed the co-expression observed between p27 and Foxa2 or Lmx1a to be indicative of an 
interaction between p27 and these two markers. However, the fact that Foxa2 and Lmx1a were 
expressed in both p27+ and p27- cells in WT controls, and that their expression pattern extended 
from the VZ to the MZ, showed that early regionalization and specification are p27-independent 
pathways, undisturbed by the absence of p27. 
Figure D.2: Layered zones of DA neuron development. DA neurons are born in the VZ (yellow 
cells) where they express Ki67, Sox2 and Ngn2 and are considered mitotic precursors. As these cells 
mature, the migrate through the IZ (orange cells), where some cells are Ngn2+ and the rest begin 
expressing p27 and Nurr1. These cell continue to migrate, losing progenitor identity and become 






 We next studied the effects of p27 on the cell cycle, by studying the marker Ki67. At 
early stages of development, we saw a significant increase in the expression of Ki67 in p27 
deficient mice, which we can expect to see in the absence of p27 (whose primary function is 
inhabiting the cell cycle; Sherr and Roberts 1999, Besson et al 2008, Abbastabar et al 2018), 
and these results were confirmed in vitro. Similar results were obtained for the neural precursor 
marker Sox2, where we saw significant increases in the absence of p27, both in vivo and in 
vitro. These results therefore allow us to conclude that p27 deficiency increases the pool of 
mitotic precursors.  
To study the effect of p27 on proliferation, we injected pregnant mice at E11.5 with 
BrdU (a thymidine analog with the ability to incorporate into newly synthesized DNA of 
actively dividing cells; Wojtowicz and Kee 2006) which were sacrificed 24 hours later at E12.5. 
We saw significant increases in BrdU expression in p27 deficient mice, confirming that p27 
deficiency increases proliferation. These results were supported by studies in primary cultures, 
showing the same result. Furthermore, we performed co-expression experiments with BrdU and 
Ki67 or Sox2, and saw that the overall number of BrdU+Ki67+ and BrdU+Sox2+ double 
positive cells also increased significantly in p27 deficient mice. Interestingly, when comparing 
the overall number of BrdU+Ki67+ and BrdU+Sox2+ double positive cells with the total 
expression of either Ki67 or Sox2 respectively, we saw that Ki67 and Sox2 were co-expressed 
almost 100% with BrdU, making these two markers an indirect measure of proliferation in the 
developing VM. To confirm this, we double stained Ki67 or Sox2 with PCNA, another marker 
of proliferation (Moldovan et al 2007). Again, we saw near 100% co-expression in all cases, 
further supporting Ki67 and Sox2 as indirect markers of proliferation and confirming that p27 
deficiency increases the pool of proliferating precursors.  
Knowing that Sox2 is expressed in the VZ, we can use the area of Sox2 expression as a 
measure of the size of the VZ in p27 deficient mice and controls. Thereby, we see a significant 
increase in the VZ in p27 deficient mice, leading to a change in the organization of the 
developmental zones in the VM, and a consequent decrease in the IZ and MZ. Furthermore, we 
have seen that the expression of p27 is exclusively complementary to the expression of Sox2, 
which suggests that p27 may have a regulatory role in the expression of Sox2 during DA neuron 
development. Previous work has shown that Sox2 expression was downregulated in 
proliferating progenitors in their final cell cycle, which was done by studying mitosis and Sox2 
expression with markers of post-mitotic neurons, but levels of cell cycle inhibitors were not 
investigated (Graham et al 2003). However, a direct relationship between p27 and Sox2 was 
shown in a later study, demonstrating that p27 directly represses Sox2 during embryonic stem 
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cell differentiation (Li et al 2012). Specifically, p27 has been shown to associate with the p130-
E2F4-SIN3A complex at the promoter of target genes to directly repress their transcription 
(Pippa et al 2012), including the Sox2-SSR2 regulatory element responsible for Sox2 
expression (Sikorska et al 2008). 
Sox2 is an established marker of all neural precursors, which make up a pool of 
precursors that can give rise to neurons, glia and oligodendrocytes (Ellis et al 2003). In the 
absence of p27, we have observed that this general pool of neural precursors is significantly 
increased. Therefore, we next investigated the neurogenesis marker Ngn2, a specific marker of 
DA neuron precursors in the context of the VM (Thompson et al 2006).  
Ngn2 is a highly conserved basic-helix-loop helix (bHLH) pro-neural transcription 
factor, which regulates neurogenesis (Martynoga et al 2012) by promoting progenitor cell cycle 
exit, initiating the development of neuronal lineages and promoting the generation of 
progenitors committed to differentiation (Ma et al 1999, Guillemot 1999, Farah  et al 2000, 
Bertrand et al 2002). For example, Ngn2 has been shown to promote primary neurogenesis in 
the cortex (Nguyen et al 2006) and has been associated with neuronal subtype specification (Ma 
et al 1999, Bertrand et al 2002). Furthermore, Ngn2 has been defined as a context-dependent 
precursor in the VM and is necessary for proper DA neuron differentiation (Andersson et al 
2006a, Kele et al 2006). Based on previous results showing a direct relationship between p27 
and Ngn2 (Nguyen et al 2006) in combination with our own results (seeing an increase in 
general precursors as defined by Sox2 but an overall decrease in the generation of DA neurons 
in the absence of p27), we expected to see a decrease in the expression of Ngn2. However, in 
p27 deficient mice, we saw a significant increase in Ngn2 expression, which maintained its 
spatiotemporal expression pattern but was much more expanded, consistent with an increased 
VZ.  
These results strongly suggest an important interplay between p27, Sox2 and Ngn2 in 
the transition from mitotic precursors to the onset of DA neuron differentiation. In order to 
study this in more detail, we investigated Ngn2 expression with Sox2. Ngn2+Sox2+ double 
positive cells indicate the specific population of precursors destined to become DA neurons. In 
p27 deficient mice, we saw a significant increase in the total number of Ngn2+Sox2+ cells, 
which is consistent with our previous observations of these two markers individually. However, 
by examining the number of Ngn2+Sox2+ cells in relation to the total number of Sox2+ cells, 
we can study the total number of precursors that are DA neuron specific. Interestingly, we saw 
a significant increase in the percentage of Ngn2+Sox2+ cells in relation to total Sox2+ cells, 
indicating that p27 deficiency specifically increases the expression of DA neuron precursors, 
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and most of these cells remain in the VZ as mitotic precursors, without affecting the 
organization of the IZ. 
We know that Sox2 is expressed in the general population of neural precursors, and that 
Ngn2 is expressed at the onset of neurogenesis, but the direct interaction between these markers 
is unknown. The absence of p27 leads to decreased inhibition of the Sox2-SRR2 promotor (Li 
et al 2012, Pippa et al 2012), thereby upregulating Sox2 expression. Since Ngn2 has been shown 
to inhibit Sox2, which later allows the up-regulation of post-mitotic neuronal markers (Bylund 
et al 2003), a similar mechanism could be occurring in the developing midbrain, where 
increased expression of Sox2 leads to a physiological response of increased Ngn2 expression 
to compensate for increased precursor levels.  
Based on our results showing increased Ngn2 expression in the absence of p27, if we 
assume a direct relationship between p27 and Ngn2, we can therefore expect to see decreased 
Ngn2 when overexpressing p27. However, we saw increased Ngn2 levels upon differentiating 
our p27-overexpressing cells, indicating that p27 overexpression increases neurogenesis, 
supported by the increased number of TH+ colonies observed in these cells. For this reason, it 
remains unclear whether p27, Sox2 and Ngn2 all function as parts of the same mechanism, or 
if p27 interacts with both Sox2 and Ngn2 in independent mechanisms that occur 
simultaneously.  
Taken together, our results show that p27 deficiency increases DA neuron-specific 
precursors but causes an overall decrease in DA neuron development. Having increased 
precursors at early stages of development could indicate that these cells eventually differentiate 
at later stages, with the effect of p27 deficiency being a developmental delay, causing an early 
increase in proliferation and a delayed onset of neurogenesis. Therefore, we studied later 
developmental stages, but saw that the effects observed at early stages were maintained as late 
as E14.5, with significant decreases detected for the markers TH and Pitx3, and increased 
expression observed for the markers Sox2, Ki67 and Ngn2. However, it does appear that the 
effects of p27 deficiency begin to improve by E13.5, as Nurr1 expression in p27 deficient mice 
was recovered to control levels. Despite the effects of p27 beginning to recover by later stages 
of development, as indicated by the recovery of Nurr1 expression at E13.5, we still see an effect 
on the normal progression of DA neuron development, where the majority of these cells at 
E13.5 remain Nurr1+TH- precursors. Whether this delay affects the integrity of the DA neurons 
that eventually develop needs to be investigated in more detail.   
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Possible Mechanism of p27 in the VM 
To explain the dilemma presented by our results, we investigated whether p27 
deficiency was preventing Ngn2+Sox2+ precursors from developing to DA neurons due to 
increased cell death. We studied both the presence of pyknotic nuclei and the expression of 
activated Casp3. Pyknotic nuclei area a morphological hallmark of apoptosis, where nuclei 
appear brighter and more fragmented. Casp3 is a protease enzyme that plays an essential role 
in programmed cell death, including apoptotic chromatin condensation and DNA fragmentation 
(Porter and Jänicke 1999). However, we did not see any differences or indication that loss of 
p27 was causing increased cell death in our embryonic mouse brain sections.  
Seeing an increase in Sox2, which indicates an increase in all neural precursors, we did 
a study to see if the phenotypic specification of these precursors was being altered in the absence 
of p27. We first studied the expression of BIII-Tub (as a marker of neurogenesis) and Gfap (as 
a marker of gliogenesis) and saw no significant changes in their expression. Furthermore, Gfap 
usually appears at later developmental stages (Miller and Gauthier 2007), and our results show 
that p27 deficiency does not alter or accelerate gliogenesis. We next studied the mRNA levels 
of specific neuronal phenotypes, such as GABA and Gad1 (GABAergic phenotype; Waite et al 
2011), Vglut1, Vglut2 and Glul (Glutamatergic phenotype; Morales and Root 2014, Root et al 
2016) and finally Sert and Tph2 (Serotonergic phenotype; Alenina et al 2006). No changes were 
observed for the mRNA levels of these markers, indicating that p27 does not alter the 
phenotypic specification of cells in the VM and the effect of p27 deficiency appears specific to 
DA neurons. 
Since p27 is best known for its function in the cell cycle (Sherr and Roberts 2004, Lim 
and Kaldis 2013), we cannot ignore the effects p27 deficiency may have on altering normal cell 
cycle biology, and how this may affect the transition from proliferating precursors to the onset 
of neurogenesis and DA neuron development. 
We first studied the effects of p27 deficiency on G1 phase cyclins. G1 is the first gap 
phase of the cell cycle, where the cell is preparing for DNA synthesis in the following S phase 
(Schafer 1998). The expression of D-type cyclins is induced in response to mitogenic signals 
(Sherr and Roberts 1999) and depends on CKIs for proper activation (LaBaer et al 1997, Cheng 
et al 1999). Of the effects observed for p27 deficiency on D-type cyclins, we saw a general 
trend indicating decreases mRNA levels, but this was not observed at all embryonic stages for 
all D-type cyclins and CDKs. However, the trend is expected and is supported by previous work 
showing a similar p27-dependent decrease in G1 phase cyclins (Hampl et al 2000, Geng et al 
2001, Bryja et al 2003). Interestingly, decreased Cyclin D levels are consistent with a longer 
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cycle and favors neurogenesis (Kaldis and Richardson 2012). However, despite decreased 
Cyclin D mRNA levels, we see increased proliferation (consistent with a shorter cycle) and less 
neurogenesis in the absence of p27. This indicates that p27 deficiency most likely increases 
proliferation by affecting a different part of the cell cycle.  
Therefore, we studied the effects of p27 deficiency on cyclins and CDKs involved in 
the G1/S transition. In simple terms, when the cell is ready to exit the cycle, decreased mitogenic 
stimuli cause D-type cyclins to release p27, which binds to and inhibits Cyclin E/A-Cdk2 
complexes, preventing their ability to phosphorylate Rb proteins (Besson et al 2008, Ludlow et 
al 1990). Hypophosphorylated Rb remains associated to E2F complexes, inhibiting their 
transcriptional abilities (Ludlow et al 1990, Sherr and Roberts 1999). In the absence of p27, we 
saw an increase in Cyclin E/A-Cdk2 mRNA levels, consistent with increased proliferation. 
Similar results were obtained for G2/M phase Cyclin B and Cdk1 mRNA levels and these results 
were also expected. 
The results for Cyclin A and B, although expected, provide another possible explanation 
for why increased Ngn2 expression does not lead to increased DA neuron development. It has 
previously been shown that increasing cyclin-CDK activity inhibits neurogenesis (Richard-
Parpaillon et al 2004, Lange and Calegari 2010). A mechanism for this was suggested when 
Cyclin A-Cdk2 overexpression inhibited primary neurogenesis in xenopus embryos (Ali et al 
2011), specifically due to the direct phosphorylation of Ngn2 on multiple sites by both Cyclin 
A and B dependent kinases, indicating a post-translational control of Ngn2 that hinders the 
induction of neuronal differentiation (Ali et al 2011). Furthermore, these post-translational 
modifications were shown to have different effects on the transcription of direct downstream 
targets of Ngn2, including Delta and NeuroD1(Hindley et al 2012).  
Delta (Dll1, a notch ligand) and NeuroD1 are important downstream targets of Ngn2 
(Sommer et al 1996, Seo et al 2007) that are involved in the process of lateral inhibition, where 
Ngn2 restricts its own activity to single progenitor cells, inhibiting its own expression in 
adjacent cells to control neuronal differentiation. In addition to Dll1, Hes1 and Hes5 are also 
important downstream targets of Ngn2 (Ohtsuka et al 1999), all three of them involved in Notch 
signaling and known to promote progenitor maintenance (Ohtsuka et al 1999). The study by 
Hindley et al., showed that the Dll1 promoter was not sensitive to increased phosphorylation of 
Ngn2 (Hindley et al 2012), leading us to believe that increased Ngn2 expression in the VM 
could perhaps be increasing the expression of genes responsible for promoting progenitor 
maintenance, despite increased expression of Cyclin A and B. However, our results at E12.5 
did not indicate alterations in the mRNA levels of Dll1, Hes1 or Hes5 in p27 deficient mice. 
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Therefore, we did a screen of NeuroD proteins, which are best known for their function in 
promoting neurogenesis by inhibiting progenitor maintenance (Seo et al 2007) and include 
NeuroD1, NeuroD2, NeuroD3 (also known as Ngn1), NeuroD4 and NeuroD6. Of these genes, 
only NeuroD1 was significantly decreased.  
NeuroD1 in the developing VM 
The ability of NeuroD1 (also NeuroD, Beta2) to convert ectodermal tissue to neurons 
was first described in 1995 (Lee et al 1995). NeuroD1 is highly expressed in the developing 
nervous system, with peak expression during development in areas such as the cortex (Chae et 
al 2004). Previous work supports the role of NeuroD1 in promoting neurogenesis as a direct 
downstream target of Ngn2 in olfactory tissue (Boutin et al 2010) and in proper development 
of the retina (Cherry et al 2011). Its expression pattern has been seen restricted mainly to post-
mitotic cells (D’Amico et al 2013) and in certain brain regions, including the cerebellum and 
hippocampus, NeuroD1 expression has been detected in fully differentiated structures, 
indicating it may also have maintenance functions in these tissues (Miyata et al 1999). 
The expression of pro-neural genes is transient, and cells exit the proliferative zone (or 
VZ) and begin to differentiate after pro-neural genes are downregulated (Bertrand et al 2002). 
The involvement of NeuroD1 in this process can be supported by its expression pattern in the 
VM. When double staining NeuroD1 with p27, we see a scattered expression with NeuroD1+ 
cells interspersed, but rarely co-expressed with p27 in the IZ. Their location outside of the VZ 
indicates their commitment to differentiation, and in the context of the VM, a likely 
commitment to a DA neuron fate.   
 The decreased expression observed for NeuroD1 in our initial screening led us to 
investigate the expression of this marker at early developmental stages and saw significant 
decreases in NeuroD1 expression in p27 deficient mice compared to controls. Its distribution 
was mainly restricted to the IZ, as seen by IHC studies, double stained with either Ngn2 or p27 
(described above). Therefore, although we did not see altered Ngn2 expression in the IZ, we do 
see decreased NeuroD1, further suggesting that Ngn2 is in some way inhibited from activating 
NeuroD1 to promote neurogenesis.  
 Since NeuroD1 has not yet been described in the context of the VM or in DA neuron 
development, we performed an experiment where we nucleofeted the NeuroD1 plasmid into 
our p27 deficient miPSCs, to see if we could recover the effect of p27 deficiency on Ngn2, and 
its ability to promote DA neuron differentiation (via NeuroD1). Our initial results show a 
significant increase in DA neuron production (quantified as TH+ colonies) in our p27KONeuroD1 
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cells as compared to p27KO controls. These results strongly support NeuroD1 as an important 
downstream factor of Ngn2, necessary to promote DA neuron development. However, these 
results are somewhat preliminary and need to be studied in further detail. 
Taken together, these results suggest both direct and indirect functions of p27 in the 
developing VM. We thereby suggest a cascade where p27 is a master regulator of proper cell 
cycle exit and onset of neurogenesis driven by Ngn2, and where p27 deficiency could have a 
direct effect on increasing Sox2 expression, which may, in turn, lead to increased Ngn2 
expression. Additionally, in the absence of p27, increased Cyclin A and B levels could directly 
phosphorylate Ngn2, decreasing its ability to activate downstream targets like NeuroD1, 
important to initiate neuronal differentiation. Therefore, we suggest a cascade where multiple 
mechanisms could be interacting simultaneously to ultimately decrease the differentiation of 
DA neurons in the VM (Figure D.3). 
Possible compensation for loss of p27 
 We earlier saw that p27 deficiency began to recover by later stages of development, and 
that Nurr1 was recovered by E13.5. Therefore, we studied the expression of p57 and p21 to see 
if altered levels in their expression could help explain, at least in part, some of this 
compensation.  
 As mentioned before, the Cip/Kip family of CKIs include the three family members 
p27, p21 and p57. These proteins share a conserved N-terminal domain which interacts with 
cyclins and CDKs to exert their inhibitory functions on the cell cycle, but they differ in the 
remainder of their sequence indicating that they may have individual functions outside the cycle 
(Besson et al 2008) 
 Some evidence suggests overlapping functions for CKIs due to their inherently 
disordered nature and the fact that they take shape upon binding to substrates (Besson et al 
2008, Bachs et al 2018). Furthermore, a knock-in model of p57 deficient mice expressing p27 
showed that most of the functions performed by p57 could also be performed by p27 (Susaki et 
al 2009). We therefore wanted to see if the opposite could also be true. Our simple studies of 
p57 mRNA levels show decreased p57 levels at early developmental stages in p27 deficient 
mice, supported by previous studies linking decreased p57 expression to decreased expression 
of the DA neuron marker Nurr1 (Joseph et al 2003). Therefore, in the context of DA neuron 
development, the partial compensation observed is unlikely due to p57 expression. We next 
investigated p21, and interestingly, saw increased mRNA levels during early developmental 
stages. Again, structural similarities between p21 and p27 suggest that they could have 
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overlapping functions (Bachs et al 2018). This is supported by an observed collaboration 
between p21 and p27, where they cooperate in the recruitment of cyclin-CDK complexes to the 
promotor of target genes to regulate transcription (Orlando et al 2015). Furthermore, embryonic 
fibroblasts that lack p27 were found to have increased p21 expression, due to an inhibitory 
effect of p27 on p21 (Gallastegui et al 2017). These recent findings support the possibility that 
p21 could be compensating, at least in part for the loss of p27 in the developing midbrain 
(Figure D.3) 
 Another important factor that we have not studied in much detail is Mash1. We chose 
to focus on Ngn2 expression, because although both Mash1 and Ngn2 have been implicated in 
DA neuron development, only Ngn2 was shown to be necessary for DA neuron differentiation 
(Kele et al 2006, Arenas et al 2015). Mash1 has previously been implicated in the specification 
of certain neuronal types (Hirsch et al 1998, Casarosa et al 1999, Pattyn et al 2004, Helms et al 
2005) and it has the ability to re-specify neuronal lineages when expressed in Ngn2 deficient 
mice (Fode et al 2000, Parras et al 2002; Bertrand et al 2002). In the context of the VM, 
Figure D.3: Possible mechanism of p27 deficiency in DA development. In the absence of p27, we 
have increased Cyclin E/A-Cdk2 activity, which hyperphosphorylates Rb proteins, causing their 
dissociation from the E2F complex, leading to cell cycle progression. This leads to increased 
proliferation and expression of the cell cycle marker Ki67 and the neural precursor marker Sox2. 
This alters the organization of the developing VM, leading to increased Ngn2 expression in the VZ, 
but decreased cell cycle exit and decreased neurogenesis. This can be caused by direct interactions 
between p27-Sox2-Ngn2 and/or indirect interactions due to increased Cyclin A dependent kinase 
activity known to phosphorylate and inactivate Ngn2. Decreased Ngn2 activity leads to decreased 
induction of neuronal differentiation as measured by decreased NeuroD1 and, decreased expression 
of DA neuron markers such as TH, Nurr1 and Pitx3. Some of these effects may be partially 




however, Mash1 does not re-specify DA neuron progenitors and has been shown to compensate 
for the loss of Ngn2 (Kele et al 2006). Due to the similar functions observed for Ngn2 and 
Mash1, we investigated the effects of p27 deficiency on Mash1 mRNA levels and saw 
significant increases in Mash1 expression throughout development. These results suggest 
another compensatory mechanism that could protect DA neuron development from p27 
deficiency.   
Future Perspectives  
 The current study has provided significant new information about p27 as a novel factor 
important for proper DA neuron development. However, these discoveries are initial studies 
that need to be investigated in much more detail in order to understand the full effect of p27 on 
the differentiation of DA neurons and the precise molecular mechanisms involved.  
Although our experiments have provided valuable information about the effects of p27 
in vivo, this thesis has been limited to the study of embryonic development, and the effects of 
p27 in post-natal or adult brains has not been studied. Although we have seen that DA neuron 
development begins to recover by E14.5 in p27 deficient mice, we have yet to determine if this 
deficiency ever fully recovers by later embryonic or post-natal stages. Furthermore, it must be 
determined if the apparent developmental delay caused by p27 deficiency affects the overall 
functionality and stability of the neurons that do eventually develop. This information is vital 
for the future applicability of p27 in new protocols for the directed differentiation of DA 
neurons in vitro.  
 Furthermore, we have seen effects that appear to be general to p27 as a cell cycle 
inhibitor, such as increased proliferation (BrdU) and increased Ki67. However, some results 
may also be specific to p27 in the context of the VM, independent of its function as a cell cycle 
inhibitor, such as the effects observed for Sox2, Ngn2 and NeuroD1. Therefore, in order to 
distinguish the effect of p27 in the VM from its function in the cell cycle, we would need to 
perform similar studies in mice carrying mutated versions of p27 (Kiyokawa et al 1996, Besson 
et al 2006) that do not allow p27 to bind to cyclins and CDKs. In the case of cell cycle 
independent functions of p27, direct interactions between p27 and Ngn2, Sox2 and NeuroD1 
should also be established. 
 Despite the limitations presented by this thesis, there is currently enough evidence of 
the effects of p27 on DA neuron development to warrant experiments using human stem cell 
systems, including human embryonic stem cells. In order to obtain p27 deficient embryonic 
stem cells, the CRISPR-Cas9 system (Doudna and Charpentier 2014) could be used, 
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specifically designing guide RNA for genomic editing to eliminate p27 from these cells. 
Overexpression can easily be studied following a similar nucleofection protocol and subsequent 
selection as performed in our murine stem cell models. Since we have seen that the re-
introduction of p27 was able to partially recover the effects of p27 deficiency, it would be of 
interest to use inducible vectors, in order to manipulate the expression of p27 at different stages 
of development. Furthermore, with an inducible vector, the effects of cyclins and CDKs on this 
process could be studied in more detail and provide valuable information about their effects on 
DA neuron development. In the event that these cyclin and CDK complexes are really 
phosphorylating and inhibiting Ngn2 in the absence of p27 (as hypothesized above), upon the 
administration of an analogous inhibitor, we could expect to see increased neurogenesis in 
response to increased, unphosphorylated Ngn2.  
 With evidence from human stem cell trials, we would also be able to begin testing new 
protocols to improve the differentiation of human stem cells towards DA neuron phenotypes. 
Several effective protocols currently exist (Chambers et al 2009, Kriks et al 2011, Kirkeby et 
al 2012, Grealish et al 2014), but none have been utilized for large scale application. Based on 
our results, we could suggest a protocol that relies on inhibiting p27 at early stages of 
development to promote the production of mitotic DA-specific precursors, and the addition of 
p27 at later stages to promote the differentiation of these precursors to fully mature DA neurons. 






















































The results from this work allow us to conclude the following: 
 
1.) p27 is expressed in the developing VM and this expression increases as development 
progresses.  
2.) p27 is co-expressed with DA neuron markers in the IZ and MZ, whereas its expression is 
absent from the VZ and complementary to proliferation markers, cell cycle markers and 
precursor markers. 
3.) p27 deficiency causes a significant decrease in DA neuron development, indicated by 
significant decreases in the markers TH, Pitx3 and Nurr1. These results were confirmed in 
vivo, in primary cultures and upon the directed differentiation of miPSC cell models.  
4.) p27 deficiency significantly increases proliferation and the pool of mitotic precursors, 
indicated by significant increases in the markers BrdU, Ki67 and Sox2. These results were 
confirmed in vivo and in primary cultures.  
5.) p27 deficiency significantly increases DA neuron specific precursors as measured by Ngn2 
and alters the distribution of these precursors by increasing the size of the VZ.  
6.) The effects observed in p27 deficient cultures can be, at least in part, recovered by the re-
introduction of p27.  
7.) The overexpression of p27 increases the differentiation of DA neurons in vitro. 
8.) NeuroD1 could be a novel factor in DA neuron development affected by p27 expression. 
Although we see increased numbers of Ngn2+ precursors, p27 could be affecting the 
progression of these DA-specific precursors by decreasing downstream NeuroD1 levels. 
This is supported by a partial recovery of DA neurons in p27 deficient cultures over-
expressing NeuroD1. 
 
In summary, we demonstrate important implications of p27 in the proper development of DA 
neurons and we believe this information will be useful for future application in the 








Los resultados de esta tesis nos permiten concluir lo siguiente: 
 
1.) p27 se expresa en el MV y su expresión aumenta según el desarrollo.  
2.) p27 se co-expresa con marcadores de ND en la zona intermedia (IZ) y en la zona del manto 
(MZ), pero su expresión es ausente de la zona ventricular (VZ) y complementaria a 
marcadores de proliferación, ciclo celular y precursores. 
3.) La deficiencia de p27 impide el desarrollo de ND, indicado por una disminución 
significativa en los marcadores TH, Pitx3 y Nurr1. Estos resultados se confirman in vivo, 
en cultivos primarios y en la diferenciación dirigida de células miPSC.  
4.) La deficiencia de p27 favorece la proliferación y el numero de precursores mitóticos, 
indicado por un aumento significativo en los marcadores BrdU, Ki67 y Sox2. Estos 
resultados se confirman in vivo y en cultivos primarios.  
5.) La deficiencia de p27 aumenta el número de precursores específicos de ND, indicado por 
un incremento significativo en el marcador Ngn2, y altera la distribución de esos 
precursores, aumentando el área de la VZ. 
6.) Se puede recuperar, por lo menos en parte, los efectos observados en los cultivos 
deficientes de p27, al re-expresar p27 en esos cultivos.  
7.) La sobreexpresión de p27 aumenta la diferenciación de ND in vitro. 
8.) NeuroD1 podría ser un factor nuevo en el desarrollo de ND, afectado por la expresión de 
p27. Aunque vemos un aumento en el número de precursores Ngn2+, p27 podría estar 




En resumen, hemos demostrado que p27 tiene un papel importante en el desarrollo de las ND 
y creemos que esa información podría ser útil para futuras aplicaciones en la diferenciación de 
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